

STIC-Biot ch/ChemLib

From: Yaen, Christopher
Sent: Wednesday, February 12, 2003 5:14 PM
To: STIC-Biotech/ChemLib
Subject: 09924103

ADS

RC 261-A 253

431992

could you please get the following ref(s):

Eur J Immunol 1996 Dec;26(12):2924-32

Nuclear Medicine Communications, (1988) 9/10 (745-752)

INTERNATIONAL JOURNAL OF CANCER, (1982 Feb 15) 29 (2) 133-7

Christopher Yaen
Patent Examiner
US PTO
Art Unit 1642
CM1-Rm 8E18
Mail Box 8E12
703-305-3586

af-RC 261-A34

COMPLETED
Scientific and Technical
Information Center

9660853 FEB 20 REC'D 96

PAT. & T.M. OFFICE

Searcher: _____
Phone: _____
Location: _____
Date Picked Up: _____
Date Completed: _____
Searcher Prep/Review: _____
Clerical: _____
Online time: _____

TYPE OF SEARCH:
NA Sequences: _____
AA Sequences: _____
Structures: _____
Bibliographic: _____
Litigation: _____
Full text: _____
Patent Family: _____
Other: _____

VENDOR/COST (where applic.)
STN: _____
DIALOG: _____
Questel/Orbit: _____
DRLink: _____
Lexis/Nexis: _____
Sequence Sys.: _____
WWW/Internet: _____
Other (specify): _____

From: Yaen, Christopher
Sent: Wednesday, February 12, 2003 5:14 PM
To: STIC-Biotech/ChemLib
Subject: 09924103

could you please get the following ref(s):

Eur J Immunol 1996 Dec;26(12):2924-32

Nuclear Medicine Communications, (1988) 9/10 (745-752)

INTERNATIONAL JOURNAL OF CANCER, (1982 Feb 15) 29 (2) 133-7

Christopher Yaen
Patent Examiner
US PTO
Art Unit 1642
CM1-Rm 8E18
Mail Box 8E12
703-305-3586

RECEIVED
FEB 13 2003
STIC-Biotech/ChemLib

Searcher: _____
Phone: _____
Location: _____
Date Picked Up: _____
Date Completed: _____
Searcher Prep/Review: _____
Clerical: _____
Online time: _____

TYPE OF SEARCH:
NA Sequences: _____
AA Sequences: _____
Structures: _____
Bibliographic: _____
Litigation: _____
Full text: _____
Patent Family: _____
Other: _____

VENDOR/COST (where applic.)
STN: _____
DIALOG: _____
Questel/Orbit: _____
DRLink: _____
Lexis/Nexis: _____
Sequence Sys.: _____
WWW/Internet: _____
Other (specify): _____



National
Library
of Medicine
NLM

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Bc

Search for 

Limits

Preview/Index

History


Clipboard

Details

About Entrez



Display



Abstract

Show: 20 

Text



Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Browser

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

1: Eur J Immunol 1996 Dec;26(12):2924-32

Related Articles, Links

CD66: role in the regulation of neutrophil effector function.

Stocks SC, Ruchaud-Sparagano MH, Kerr MA, Grunert F, Haslett C, Dransfield I.

Unit of Respiratory Medicine, University of Edinburgh Medical School, Scotland.

Neutrophils express several heavily glycosylated carcinoembryonic antigen (CEA)-related glycoproteins (CD66 antigens) which have been implicated in adhesion to E-selectin and as receptors for the lectins galectin 3 and bacterial type-1 fimbriae. The role of the CD66 antigens in neutrophil effector function was examined using non-cross-reacting and cross-reacting domain-mapped CD66 monoclonal antibody (mAb), which recognize epitopes on biliary glycoprotein (BGP; CD66a), CEA gene family member 6 (CGM6; CD66b), nonspecific cross-reacting antigen 90 (NCA90; CD66c) or CGM1 (CD66d). We show that BGP-specific mAb which recognize an AB-domain epitope strongly augment adhesion to fibrinogen by an Fc receptor- and beta2 integrin-dependent mechanism. Co-ligation of BGP with the glycoprophosphatidylinositol (GPI)-anchored CGM6 and NCA90 also caused increased beta2 integrin-mediated adhesion, receptor clustering and priming of formyl-Met-Leu-Phe (fMLP)-induced oxidant production by neutrophils, but only a small change in expression of L-selectin and CR3 compared to the chemotactic peptide fMLP. Ligation of CGM6 or NCA90 alone did not cause activation of the neutrophil in any of the assays used and did not cause priming of fMLP-induced oxidant production even when a secondary cross-linking reagent was used. We propose that specific cross-linking of neutrophil BGP with CGM6 and NCA90 contributes significantly to the regulation of neutrophil function during neutrophil recruitment.

PMID: 8977287 [PubMed - indexed for MEDLINE]



Display



Abstract



Text



[Write to the Help Desk](#)

Connecting via Winsock to STN

Welcome to STN International! Enter x:x
LOGID:sspt1162cxy

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * *

Welcome to STN International

* * * * *

Web Page URLs for STN Seminar Schedule - N. America

* * * * *

"Ask-CNS" for self-help around the clock

* * * * *

RELISTBIN: Reload and Implementation of a New Subject Area

* * * * *

NEWS 3 Apr 09 ZDB will be removed from STN

* * * * *

NEWS 4 Apr 09 US Patent Applications available in IPI/CDB, IPI/PAT, and IPI/DB

* * * * *

NEWS 5 Apr 19 Records from IP.com available in CAPUS, NCARUS, and ZCARUS

* * * * *

NEWS 6 Apr 22 BIOSIS Gene Names now available in TOXCENTRE

* * * * *

NEWS 7 Apr 22 Federal Research in Progress (FEDRIP) now available

* * * * *

NEWS 8 Jun 03 New e-mail delivery for search results now available

* * * * *

NEWS 9 Jun 10 MEDLINE Reload

* * * * *

NEWS 10 Jun 10 PCTFULL has been reloaded

* * * * *

NEWS 11 Jun 10 FOREX no longer contains STANDARDS file segment

* * * * *

NEWS 12 Jul 02 USAN to be reloaded July 28, 2002;

* * * * *

NEWS 13 Jul 22 Enhanced polymer searching in REGISTRY

* * * * *

NEWS 14 Jul 29 NETFIRST to be removed from STN

* * * * *

NEWS 15 Jul 30 CANCERLIT reload

* * * * *

NEWS 16 Aug 08 PHARMmarketletter (PHARMALERT) - new on STN

* * * * *

NEWS 17 Aug 08 NTIS has been reloaded and enhanced

* * * * *

NEWS 18 Aug 08 NTIS has been reloaded and enhanced

* * * * *

NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)

* * * * *

NEWS 20 Aug 19 now available on STN

* * * * *

NEWS 21 Aug 19 IPI/PAT, IPI/CDB, and IPI/DB have been reloaded

* * * * *

NEWS 22 Aug 26 The MEDLINE file segment of TOXCENTRE has been reloaded

* * * * *

NEWS 23 Sep 03 Sequence searching in REGISTRY enhanced

* * * * *

NEWS 24 Sep 16 JAPOL has been reloaded and enhanced

* * * * *

NEWS 25 Sep 16 Experimental properties added to the REGISTRY file

* * * * *

NEWS 26 Oct 01 CA Section Thesaurus available in CAPUS and CA

* * * * *

NEWS 27 Oct 21 EVENTLINE has been reloaded

* * * * *

NEWS 28 Oct 24 BETSTEIN adds new search fields

* * * * *

NEWS 29 Oct 24 Nutraceuticals International (NUTRACUT) now available on STN

* * * * *

NEWS 30 Oct 25 MEDLINE SDI run on October 8, 2002

* * * * *

NEWS 31 Nov 18 DKIIT has been renamed APODIL

* * * * *

NEWS 32 Nov 25 More calculated properties added to REGISTRY

* * * * *

NEWS 33 Dec 02 TIBKAT will be removed from STN

* * * * *

NEWS 34 Dec 04 CSA files on STN

* * * * *

NEWS 35 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date

* * * * *

NEWS 36 Dec 17 TOXCENTRE enhanced with additional content

* * * * *

NEWS 37 Dec 17 Adis Clinical Trials Insight now available on STN

* * * * *

NEWS 38 Dec 30 ISMEC no longer available

* * * * *

NEWS 39 Jan 13 Indexing added to some pre-1967 records in CA/CAPUS

* * * * *

NEWS 40 Jan 21 NUTRACUT offering one free connect hour in February 2003

* * * * *

NEWS 41 Jan 21 PHARMAL offering one free connect hour in February 2003

* * * * *

NEWS 42 Jan 29 Simultaneous left and right truncation added to COMPENDEX,

* * * * *

NEWS 43 ENERGY, INSPPEC

* * * * *

NEWS 44 EXPRESS

* * * * *

NEWS 45 CURRENT

* * * * *

NEWS 46 MACINTOSH

* * * * *

NEWS 47 VERSION

* * * * *

NEWS 48 CURRENT

* * * * *

NEWS 49 DISCOVER

* * * * *

NEWS 50 FILE

* * * * *

NEWS 51 FILE

* * * * *

NEWS 52 FILE

* * * * *

NEWS 53 FILE

* * * * *

NEWS 54 FILE

* * * * *

NEWS 55 FILE

* * * * *

NEWS 56 FILE

* * * * *

NEWS 57 FILE

* * * * *

NEWS 58 FILE

* * * * *

NEWS 59 FILE

* * * * *

NEWS 60 FILE

* * * * *

NEWS 61 FILE

* * * * *

NEWS 62 FILE

* * * * *

NEWS 63 FILE

* * * * *

NEWS 64 FILE

* * * * *

NEWS 65 FILE

* * * * *

NEWS 66 FILE

* * * * *

NEWS 67 FILE

* * * * *

NEWS 68 FILE

* * * * *

NEWS 69 FILE

* * * * *

NEWS 70 FILE

* * * * *

NEWS 71 FILE

* * * * *

NEWS 72 FILE

* * * * *

NEWS 73 FILE

* * * * *

NEWS 74 FILE

* * * * *

NEWS 75 FILE

* * * * *

NEWS 76 FILE

* * * * *

NEWS 77 FILE

* * * * *

NEWS 78 FILE

* * * * *

NEWS 79 FILE

* * * * *

NEWS 80 FILE

* * * * *

NEWS 81 FILE

* * * * *

NEWS 82 FILE

* * * * *

NEWS 83 FILE

* * * * *

NEWS 84 FILE

* * * * *

NEWS 85 FILE

* * * * *

NEWS 86 FILE

* * * * *

NEWS 87 FILE

* * * * *

NEWS 88 FILE

* * * * *

NEWS 89 FILE

* * * * *

NEWS 90 FILE

* * * * *

NEWS 91 FILE

* * * * *

NEWS 92 FILE

* * * * *

NEWS 93 FILE

* * * * *

NEWS 94 FILE

* * * * *

NEWS 95 FILE

* * * * *

NEWS 96 FILE

* * * * *

NEWS 97 FILE

* * * * *

NEWS 98 FILE

* * * * *

NEWS 99 FILE

* * * * *

NEWS 100 FILE

* * * * *

NEWS 101 FILE

* * * * *

NEWS 102 FILE

* * * * *

NEWS 103 FILE

* * * * *

NEWS 104 FILE

* * * * *

NEWS 105 FILE

* * * * *

NEWS 106 FILE

* * * * *

NEWS 107 FILE

* * * * *

NEWS 108 FILE

* * * * *

NEWS 109 FILE

* * * * *

NEWS 110 FILE

* * * * *

NEWS 111 FILE

* * * * *

NEWS 112 FILE

* * * * *

NEWS 113 FILE

* * * * *

NEWS 114 FILE

* * * * *

NEWS 115 FILE

* * * * *

NEWS 116 FILE

* * * * *

NEWS 117 FILE

* * * * *

NEWS 118 FILE

* * * * *

NEWS 119 FILE

* * * * *

NEWS 120 FILE

* * * * *

NEWS 121 FILE

* * * * *

NEWS 122 FILE

* * * * *

NEWS 123 FILE

* * * * *

NEWS 124 FILE

* * * * *

NEWS 125 FILE

* * * * *

NEWS 126 FILE

* * * * *

NEWS 127 FILE

* * * * *

NEWS 128 FILE

* * * * *

NEWS 129 FILE

* * * * *

NEWS 130 FILE

* * * * *

NEWS 131 FILE

* * * * *

NEWS 132 FILE

* * * * *

NEWS 133 FILE

* * * * *

NEWS 134 FILE

* * * * *

NEWS 135 FILE

* * * * *

NEWS 136 FILE

* * * * *

NEWS 137

| | | |
|---|--|--|
| PA | Xia, Min, Newbury Park, CA, UNITED STATES | 1993-126122, filed on 23 SEP 1993, ABANDONED Continuation of Ser. No. US 5614187 |
| Cravero, Roger, Thousand Oaks, CA, UNITED STATES | 1991-797555, filed on 22 Nov 1991, ABANDONED | |
| Angen, Inc., A Corporation of the State of Delaware (U.S. corporation) | US 20030404106 Al 20030102 | |
| PI | US 2002-133833 Al 20020506 (10) | |
| AI | US 1999-170191P 19991210 (50) | |
| RLI | US 2000-18853P 20000309 (60) | |
| PRAI | US 2000-194521P [7] US 2000-195910P 20000404 (60) | |
| DT | Utility | |
| FS | APPLICATION | |
| LN.CNT | LN.CNT | |
| INCL | INCL | |
| INCLS: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000 | INCLM: 435/325.000 | |
| NCLM: 514/012.000 | INCLM: 435/323.210; 435/456.000 | |
| NCL: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000 | INCLM: 435/325.000 | |
| IC | INCL: 434/093.210; 435/456.000 | |
| [7] | [7] | |
| ICM: A61K038-17 | ICM: A61K048-00 | |
| ICCS: C07H011-04; C12P021-02; C12N005-06; C07K014-705 | ICCS: C12N015-867 | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | CAS INDEXING IS AVAILABLE FOR THIS PATENT. | |
| L3 | ANSWER 2 OF 14 USPATFULL | |
| AN | 2002-300805 USPATFULL | |
| IN | 2002-168348 Al 20021114 | |
| PI | US 2001-874512 Al 20010605 (9) | |
| AI | Continuation of Ser. No. US 1998-126704, filed on 30 Jul 1998, ABANDONED | |
| RLI | Continuation of Ser. No. US 1995-452020, filed on 1 Jun 1995, GRANTED | |
| Pat. No. US 5876708 Continuation-in-part of Ser. No. US 1994-266427, filed on 27 Jun 1994, GRANTED, Pat. No. US 5614187 Continuation-in-part of Ser. No. US 1995-451201, filed on 26 May 1995, GRANTED, Pat. No. US 629846 Continuation of Ser. No. US 1992-838595, filed on 19 Feb 1992, ABANDONED Continuation of Ser. No. US 1994-220371, filed on 29 Mar 1994, UNKNOWN Continuation of Ser. No. US 1994-436533, filed on 16 May 1994, GRANTED, Pat. No. US 5624823 Continuation of Ser. No. US 1993-114072, filed on 30 Aug 1993, GRANTED, Pat. No. US 5624828 Continuation of Ser. No. US 1993-150738, filed on 10 Nov 1993, UNKNOWN Continuation of Ser. No. US 1994-212228, filed on 14 Mar 1994, UNKNOWN Continuation of Ser. No. WO 1994-US1615, filed on 14 Feb 1994, UNKNOWN Utility Application | | |
| FS | APPLICATION | |
| LN.CNT | LN.CNT | |
| INCL | INCL | |
| INCLS: 435/069.100; 530/350.000; 536/023.500; 800/008.000; 514/044.000 | INCLM: 435/325.000; 530/350.000; 536/023.500; 800/008.000; 514/044.000 | |
| NCLM: 514/012.000 | INCLM: 435/323.210; 435/456.000 | |
| NCL: 530/350.000; 536/023.500; 435/069.100 | INCL: 434/093.210; 435/456.000 | |
| IC | INCL: 435/325.000; 530/350.000; 536/023.500; 800/008.000; 514/044.000 | |
| [7] | [7] | |
| ICM: A61K067-00 | ICCS: A61K048-00; C07H021-04; C12P021-02; C07K014-715 | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | CAS INDEXING IS AVAILABLE FOR THIS PATENT. | |
| L3 | ANSWER 4 OF 14 USPATFULL | |
| AN | 2002-85173 USPATFULL | |
| TI | II-17 receptor like molecules and uses thereof | |
| IN | Jing, Shuang, Thousand Oaks, CA, UNITED STATES | |
| PI | US 2002045213 Al 20020418 | |
| RLI | Continuation-in-part of Ser. No. US 2000-724460, filed on 28 Nov 2000, PENDING | |
| Pat. No. US 2001-09567 Al 20010315 (9) | Pat. No. US 2001-09567 Al 20010315 (9) | |
| AI | Utility | |
| PRAI | Utility | |
| DT | Utility | |
| FS | APPLICATION | |
| LN.CNT | LN.CNT | |
| INCL | INCL | |
| INCLS: 435/069.100; 530/350.000; 536/023.500; 800/008.000; 514/044.000 | INCLM: 435/325.000; 530/350.000; 536/023.500; 800/008.000; 514/044.000 | |
| NCLM: 514/012.000 | INCLM: 435/323.210; 435/456.000 | |
| NCL: 530/350.000; 536/023.500; 435/069.100 | INCL: 434/093.210; 435/456.000 | |
| IC | INCL: 435/325.000; 530/350.000; 536/023.500; 800/008.000; 514/044.000 | |
| [7] | [7] | |
| ICM: A61K048-00 | ICCS: A61K048-00; C07H021-04; C12P021-02; C07K014-715 | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | CAS INDEXING IS AVAILABLE FOR THIS PATENT. | |
| L3 | ANSWER 5 OF 14 USPATFULL | |
| AN | 2002-66871 USPATFULL | |
| TI | II-17 like molecules and uses thereof | |
| IN | Medlock, Eugene, Westlake Village, CA, UNITED STATES | |
| Pat. No. US 2001-09567 Al 20010315 (9) | Pat. No. US 2001-09567 Al 20010315 (9) | |
| PI | Utility | |
| RLI | Continuation-in-part of Ser. No. US 2001-810384, filed on 16 Mar 2001, PENDING | |
| Pat. No. US 2000-266159P 20010202 (60) | Pat. No. US 2000-266159P 20010202 (60) | |
| PRAI | Utility | |
| DT | Utility | |
| FS | APPLICATION | |
| LN.CNT | LN.CNT | |
| INCL | INCL | |
| INCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.500; 530/350.000 | INCLM: 435/069.100; 435/325.000; 435/320.100; 536/023.500; 530/350.000 | |
| NCLM: 514/012.000 | INCLM: 435/069.100; 435/325.000; 435/320.100; 536/023.500; 530/350.000 | |
| NCL: 530/350.000; 536/023.500; 435/069.100 | INCL: 434/093.210; 435/456.000 | |
| IC | INCL: 435/325.000; 530/350.000; 536/023.500; 800/008.000; 514/044.000 | |
| [7] | [7] | |
| ICM: C12P021-04 | ICCS: C12P021-04; C12N005-06; C12P021-02 | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | CAS INDEXING IS AVAILABLE FOR THIS PATENT. | |
| L3 | ANSWER 6 OF 14 USPATFULL | |
| AN | 2002-37315 USPATFULL | |

TI Immunotherapy for chronic myelocytic leukemia
IN Goldenberg, David M.; Mendham, NJ, UNITED STATES
PI Hansen, Hans J.; Sidell, LN, UNITED STATES
AI US 2002022131 Al 20020221
PRAI US 2001-924103 Al 20010808 (9)
DT Utility
FS APPLICATION
LN/CNT 1133
INCL INCHM: 424/155.100
NCL NCIM: 424/155.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L3 ANSWER 7 OF 14 USPATFULL
AN 2002:16578 USPATFULL
TI Composition and method for treating inflammatory diseases
IN Boone, Thomas C., Newbury Park, CA, UNITED STATES
RLI Herrenson, Susan, Newbury Park, CA, UNITED STATES
PA Bevilacqua, Michael P., Boulder, CO, UNITED STATES
PA Collins, David S., Fishers, IN, UNITED STATES
PA Agen Inc. (U.S. corporation)
PI US 20020059454 Al 20020124
AI US 2001-784623 Al 20010215 (9)
RLI Division of Ser. No. US 1988-131247, filed on 7 Aug 1998, PENDING
WO 1997-US2131 19970210
DT Utility
FS APPLICATION
LN/CNT 3525
INCL INCHM: 424/178.100
NCL NCIM: 424/178.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L3 ANSWER 8 OF 14 USPATFULL
AN 2001:185089 USPATFULL
TI Specific tolerance in transplantation
IN Sachs, David H., Newton, MA, United States (U.S. corporation)
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
PI US 6306651 B1 20011023
AI US 1997-910287 19970913 (8)
RLI Continuation of Ser. No. US 1996-759404, filed on 4 Dec 1996, now abandoned Continuation of Ser. No. US 1994-266427, filed on 27 Jun 1994, now patented, Pat. No. US 561187 Continuation of Ser. No. US 1993-126122, filed on 23 Sep 1993, now abandoned Continuation of Ser. No. US 1991-97555, filed on 22 Nov 1991, now abandoned
DT Utility
FS GRANTED
LN/CNT 1384
INCL INCHM: 435/325.000
INCHS: 435/366.000; 435/372.000; 424/093.200; 424/093.210
NCL NCIM: 435/355.000
NCIS: 424/093.200; 424/093.210; 435/366.000; 435/372.000
IC [7]
ICM: C12N015-95
ICG: A61K035-00
EXF 424/93.1; 424/93.21; 435/315; 435/366; 435/372
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L3 ANSWER 9 OF 14 USPATFULL
AN 2001:162845 USPATFULL

TI Composition and method for treating inflammatory diseases
IN Boone, Thomas C., Newbury Park, CA, United States
RLI Herrenson, Susan, Newbury Park, CA, United States
PA Bevilacqua, Michael P., Boulder, CO, United States
PA Collins, David S., Fishers, IN, United States (U.S. corporation)
PI US 6299170 B1 20010925
AI US 1998-131247 19980807 (9)
PRAI US 1997-55185P 19970808 (60)
DT Utility
FS GRANTED
LN/CNT 3022
INCL INCHM: 424/134.100
NCL NCIM: 514/012.000; 530/324.000
IC [7]
ICM: A61K038-00
ICIS: A61K039-395
EXF 424/134.1; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L3 ANSWER 10 OF 14 USPATFULL
AN 2000:98413 USPATFULL
TI Composition and method for treating inflammatory diseases
IN Collins, David S., Lafayette, CO, United States
RLI Bevilacqua, Michael P., Boulder, CO, United States
PA Agen Inc., Thousand Oaks, CA, United States (U.S. corporation)
PI US 6096728 20000801
AI US 1997-78414 19970207 (8)
PRAI US 1996-114199 19960209 (60)
DT Utility
FS Granted
LN/CNT 2432
INCL INCHM: 514/062.000
NCL NCIM: 530/351.000
IC [7]
ICM: A61K031-70
ICG: C07K001-00
EXF 514/62; 530/351
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L3 ANSWER 11 OF 14 USPATFULL
AN 1999-27177 USPATFULL
TI Allogeneic and xenogeneic transplantation
IN Sachs, David H., Newton, MA, United States (U.S. corporation)
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
PI US 5876708 19950601 (8)
AI US 1995-458770 19950601 (8)
RLI Continuation-in-part of Ser. No. US 1994-266427, filed on 27 Jun 1994, now patented, Pat. No. US 561187 and Ser. No. US 1995-451210, filed on 26 May 1995 which is a continuation of Ser. No. US 1995-438595, filed on 26 May 1995, now abandoned And a continuation-in-part of Ser. No. US 1994-220371, filed on 29 Mar 1994, now abandoned Ser. No. Ser. No. US 1994-43533, filed on 16 May 1994, now patented. Pat. No. US 5685564 Ser. No. Ser. No. US 1993-114072, filed on 30 Aug 1993, now patented.

Pat. No. US 5624823 Ser. No. Ser. No. US 1993-150739, filed on 10 Nov 1993, now abandoned And Ser. No. US 1994-212228, filed on 14 Mar 1994, now abandoned

DT Utility

FS Granted

LN CNT 3555

NCL INCLM: 424/093.100
INCUS: 435/325.000
NCLS: 424/093.100
[61] ICLM: A61K035-00
IC5: C12N005-08
EXF 424/93.1; 424/93.21; 435/32.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 12 OF 14 USPATFULL
AN 97-24710 USPATFULL
TI Specific tolerance in transplantation
IN Sachs, David H.; Newton, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S. Corporation)
The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 5614187
AI US 1994-266427 19940627 (8)
RLI Continuation of Ser. No. US 1993-126122, filed on 23 Sep 1993, now abandoned which is a continuation of Ser. No. US 1991-797555, filed on 22 Nov 1991, now abandoned

DT Utility
FS Granted

LN CNT 1304
INCLM: 424/093.210
INCUS: 424/093.310; 424/577.000; 536/023.100; 536/023.500; 435/172.300
NCL NCLS: 424/093.210
[61] ICLM: C12N015-00
IC5: A01N63/00; A61K035-26; C07H021-04
EXF 424/93.21; 435/172.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 14 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 92073974 EMBASE
DN 1992073974

TI determination of anti-neutrophil cytoplasm antibodies (ANCA) specificity by immunofluorescence on chronic myelocytic leukemia cells.

AU Chevallier A.; Noel L.H.; Reiner G.; Gardembas-Pain M.; Subra J.F.; Nusbaum P.; Hurez D.; Lessure P.

CS Laboratoire d'Immunopath., CHU, 49040 Angers Cedex, France

SO Journal of Immunological Methods, (1992) 147/1 (101-109).
ISSN: 0022-1759 CODEN: JIMMBG

CY Netherlands

DT Journal, Article

FS 016 Cancer
025 Hematology
026 Immunology, Serology and Transplantation
LA English
SL English

L3 ANSWER 14 OF 14 MIDDLELINE
DN 83135146 MIDDLELINE
DN 83133146 Pubmed ID: 6962202

TI Monoclonal antibodies against human granulocytes and myeloid differentiation antigens.

L3 ANSWER 1 OF 14 USPATFULL
DETD [0091] Anti-classe I Cell-Mediated Lympholysis (CML) Assay: Spleens are removed from BMT recipients and normal mice, red cells are lysed using CML buffer, and a single, is used as culture supernatant, and will be stained by mouse anti-rat IgG-specific mab Mar10.5; FITC-labelled rat-anti-mouse granulocyte antibody Gr1 is purchased from Pharmingen; FITC-labelled rat-anti-mouse IgM mab is purchased from Zymed; FITC-labelled rat-anti-mouse Thy1.2 mab will be purchased as confirmed by FCM. These chimeras recover normal cellular immune function 2-3 months after BMT, as tested by MLR and CML. Four such chimeric animals (see Table 1, numbers 1-4) received kidney transplants from donors class II matched to BMT donors. Tumolointestinal infiltrate without signs of vascular injury. Both long-term survivors (pigs #3 & 5) were recently tested for anti-donor reactivity. CML and MLR revealed specific unresponsiveness to the kidney transplant donor type cells. Pigs #8-10 received kidney transplant from outbred Yorkshire.

L3 ANSWER 3 OF 14 USPATFULL
DETD [0091] Anti-classe I Cell-Mediated Lympholysis (CML) Assay: Spleens are removed from BMT recipients and normal mice, red cells are lysed using CML buffer, and a single, is used as culture supernatant, and will be stained by mouse anti-rat IgG-specific mab Mar10.5; FITC-labelled rat-anti-mouse granulocyte antibody Gr1 is purchased from Pharmingen; FITC-labelled rat-anti-mouse Thy1.2 mab will be purchased as following TNF inhibitors: TNF binding proteins (soluble TNF receptor type-I and soluble TNF receptor type-II ("sTNFRs"), as defined herein), anti-TNF antibodies, granulocyte colony-stimulating factor, thalidomide, BN 50730; tenidap; E 5531; tiapafant PCA 4248; nimusulide; panavir; rolipram; RP 73401; peptide T; MDL.

=> d KWIC 1-14

L3 ANSWER 1 OF 14 USPATFULL
DETD tumor cells. Examples of such diseases include, but are not limited to, lymphomas, bone sarcoma, chronic and acute myelogenous leukemia (CML and AML) and other leukemias, multiple myeloma, lung cancer, breast cancer, tumor metastasis, and side effects from radiation therapy. Other following TNF inhibitors: TNF binding proteins (soluble TNF receptor type-I and soluble TNF receptor type-II ("sTNFRs"), as defined herein), anti-TNF antibodies, granulocyte colony-stimulating factor, thalidomide, BN 50730, tenidap, E 5531, tiapafant PCA 4248, nimusulide, panavir, rolipram, RP 73401, peptide T, MDL.

L3 ANSWER 2 OF 14 USPATFULL
DETD Immuno 9-301 is used as culture supernatant, and will be stained by mouse anti-rat IgG-specific mab Mar1 8.5; FITC-labelled rat-anti-mouse granulocyte antibody Gr1 is purchased from Zymed; FITC-labelled rat-anti-mouse Thy1.2 mab will be purchased from Becton-Dickinson; FITC-labelled mouse-anti-human CD3 mab Leu4 (Becton).

L3 ANSWER 3 OF 14 USPATFULL
DETD [0091] Anti-classe I Cell-Mediated Lympholysis (CML) Assay: Spleens are removed from BMT recipients and normal mice, red cells are lysed using CML buffer, and a single, is used as culture supernatant, and will be stained by mouse anti-rat IgG-specific mab Mar10.5; FITC-labelled rat-anti-mouse granulocyte antibody Gr1 is purchased from Pharmingen; FITC-labelled rat-anti-mouse Thy1.2 mab will be purchased as following TNF inhibitors: TNF binding proteins (soluble TNF receptor type-I and soluble TNF receptor type-II ("sTNFRs"), as defined herein), anti-TNF antibodies, granulocyte colony-stimulating factor, thalidomide, BN 50730; tenidap; E 5531; tiapafant PCA 4248; nimusulide; panavir; rolipram; RP 73401; peptide T; MDL.

L3 ANSWER 5 OF 14 USPATFULL

DET'D examples of such diseases include, but are not limited to, lymphomas, bone sarcoma, chronic and acute myelogenous leukemia (AML) and other

CML, including myelomonocytic leukemia, lung, breast cancer, tumor metastasis, and side effects from radiation.

DET'D following TNF inhibitors: TNF binding proteins (soluble TNF receptor type-I and soluble TNF receptor type-II ("TNFRs"), as defined herein, anti-TNF antibodies, granulocyte colony stimulating factor; thalidomide; BN 50730; tenipap; E 5531; tiapafant PCA 4248; nimuside; panavir; rolipram; RP 73401; peptide T; MDL

including useful in the diagnosis, treatment and prevention of lymphomas myelogenous leukemia (M3 AML), myelomonocytic leukemia (M4 AML) and CML including non-hodgkin's lymphoma and hodgkin's disease; acute leukemia (M3 AML), myelomonocytic leukemia (M4 AML); acute lymphocytic leukemia (M5 AML) and megakaryocytic leukemia (M7 AML); acute lymphocytic leukemia including.

L3 ANSWER 6 OF 14 USPATFULL

Immunotherapy utilizing naked anti-granulocyte antibodies provides an effective means for treating chronic myelocytic leukemia (CML). Such antibodies can be administered alone or in combination with other therapies, such as immunoconjugates or chemotherapeutics. In either format, an effective therapy for treating CML is provided, which avoids the toxic side effects typically associated with cancer therapy. The disclosed immunotherapy also is effective for treating.

[0001] Chronic myelocytic leukemia (CML) is a highly specific disease that is defined by strict hematologic parameters that include a pathognomonic differential leukocyte count. Usually, CML is accompanied by the presence, in bone marrow cells, of the Ph chromosome, the first chromosomal anomaly to be regularly observed as a differentiated neoplasm and responds very well to simple, nonintensive therapy. After a variable interval, CML metastasizes to therapy, even when intensive. See Spiers, Semin. Oncol., 22(4):380-95 (1995). At the stage of metamorphosis, a great variety of clinical and hematologic pictures occur, and CML may mimic a myelodysplasia, a subacute leukemia, acute myelocytic leukemia (AML), or acute lymphocytic leukemia (ALL). The, from the chronic phase to a so-called blastic crisis is incorrect. See Spiers, Semin. Oncol., 22(4):380-95 (1995). In most cases, CML is observed to undergo two or more stepwise evolutions, e.g., from chronic phase to an accelerated myeloproliferative phase to

[0002] A variety of therapies have been used to treat CML. Traditional methods for treating leukemia, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. The use of duration of such treatments. Another therapy, allogeneic bone marrow transplants, has had the largest impact on survival among patients with CML. See Clarkson, J. Clin. Oncol., 3:135-139 (1985). Like the previous therapies, however, bone marrow transplants are poorly tolerated by patients.

[0005] There is a need, therefore, to develop immunotherapies which utilize naked antibodies to treat CML. Such therapies would cost-effectively treat patients without inducing toxic side-effects. SUMM objects, there is provided, in accordance with one aspect of the present invention, a method for treating chronic myelocytic leukemia (CML) in a patient, comprising administering to the patient a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one naked anti-granulocyte antibody. A variety of anti-granulocyte antibodies can be used in the present invention. Examples include, but are not limited to, anti-NCA-90, anti-NCA-95, MN-2, MN-15, NP-1 and NP2. In one embodiment,

a single, naked anti-granulocyte antibody is administered to a patient while, in another, more than one anti-granulocyte antibody is administered.

in still another embodiment, at least one naked anti-granulocyte antibody is administered to a patient in combination with naked antibodies directed to antigens present on a single granulocyte precursor, such.

[0008] In another embodiment of the present invention, naked anti-

granulocyte antibodies are used in combination with other cancer therapies, e.g., an immunoconjugate or chemotherapy.

Preferred immunoconjugates include radiolabeled antibody components and conjugates of an anti-granulocyte antibody component

and an immunomodulator, such as a cytokine, stem cell growth factor, lymphotxin or hematopoietic factor. In still another embodiment, naked anti-

granulocyte antibodies are administered in combination with inducing agent which either enhance or induce the expression of the targeted antigen. Such inducing

Accordingly, the antibodies of the present invention can be used to treat AML, as well as CML.

SUMM a patient, comprising administering to the patient a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one naked anti-granulocyte antibody and an inducing agent, wherein the inducing agent induces expression of antigens which are minimally displayed on the surface of myeloblasts. As described above, the inventive method can be further combined with other naked, anti-granulocyte antibodies, antibody-toxin fusion proteins and other cancer therapies, e.g., an immunoconjugate or chemotherapy.

[0012] The present invention provides improved methods for treating myelocytic leukemia, particularly CML. The inventive methods utilize naked granulocyte-specific antibodies to destroy myeloid leukemia cells without the toxic side-effects normally associated with previous.

[0013] The anti-granulocyte antibodies used in the present invention are directed to antigens associated with various cell-types in the granulocyte lineage, unlike in AML, malignant myeloblasts of CML patients differentiate into a variety of cell-types, including myelocytes, metamyelocytes, bands, and

granulocytes. Accordingly, immunotherapy directed to one or two, inventive therapy, recognize immature and mature granulocytes, the present invention provides an effective method for ridding malignant cells from a CML patient's bone marrow.

SUMM [0014] A variety of anti-granulocyte antibodies can be used in the present invention. In one embodiment the inventive methods utilize anti-NCA-90 antibodies. A preferred example of.

SUMM [0020] The term "anti-granulocyte antibody" refers to an antibody which recognizes an antigen which is present on two or more cell-types of the granulocyte/myelocyte lineage.

[0057] The present invention contemplates the use of naked anti-granulocyte antibodies as the primary therapeutic composition of CML. However, in one embodiment of the invention, naked anti-granulocyte antibodies, e.g., MN-3 or MN-2, are administered to a patient in combination with one or more immunoconjugates. Such immunoconjugates can be.

SUMM [0077] Therapeutic Use of Anti-Granulocyte Antibodies SUMM the present invention provides an effective method for ridding malignant cells from a patient with myelocytic leukemia, in particular CML. As discussed above, a variety of anti-granulocyte antibodies can be used in the inventive therapy.

SUMM [0079] The present invention contemplates the use of naked anti-granulocyte antibodies as the primary therapeutic composition for treatment of CML. Such a composition can contain polyclonal anti-granulocyte antibodies or

monoclonal anti-granulocyte antibodies

[0080] Methods for determining the binding specificity of an anti-granulocyte antibody are well-known to those of skill in the art. General methods are provided, for example, by Manson (ed.), *Methods in Cell Biology* (1981). In another embodiment of the present invention, naked anti-granulocyte antibodies can be used in combination with other cancer therapies, e.g., an immunoconjugate or chemotherapy. Such combination regimens are advantageous over multimodal regimens, the supplemental therapeutic compositions can be administered before, concurrently, or after administration of the naked anti-granulocyte antibodies.

[0082] Preferred immunoconjugates include radiolabeled antibody components and conjugates of an anti-granulocyte antibody component and an immunomodulator. A radiolabeled immunoconjugate may comprise an alpha-emitting radioisotope, a beta-emitting radioisotope, a gamma-emitting radioisotope, an Auger-emitting radioisotope, or a combination of two or more antibody moieties.

[0083] In another embodiment, combination therapy utilizing naked, anti-granulocyte antibodies can comprise antibody-toxin fusion proteins. An antibody-toxin fusion protein is a fusion protein that comprises one or more antibody moieties.

[0084] Multimodal therapies of the present invention further include immunotherapy comprising two or more naked anti-granulocyte antibodies. In another embodiment, multimodal therapy comprises administration of naked anti-granulocyte antibodies supplemented with naked antibodies directed to antigens present on a single granulocyte precursor. For example, naked MN-3 antibodies can be.

[0085] **Tissue Antigens**, 52:1-8 (1998). Accordingly, the antibodies of the present invention can be used to treat AML, as well as CML.

[0086] In another form of multimodal therapy, subjects receive naked anti-granulocyte antibodies and standard chemotherapy. Examples of chemotherapeutic agents include, but are not limited to, daunorubicin, cytarabine, 6-thioguanine, etoposide, mitoxantrone, diziquone, idarubicin, and teniposide.

[0087] In general, the dosage of administered naked anti-granulocyte antibodies, immunoconjugates, fusion proteins and additional therapeutics will vary depending upon such factors as the patient's age, weight, height, sex, general health, and the present invention can be administered at low protein doses, such as 20 to 1500 milligrams protein per dose, given once, or repeatedly, parenterally.

[0088] Alternatively, naked anti-granulocyte antibodies are administered in doses of 20 to 1000 milligrams protein per dose, or 20 to 500 milligrams protein per dose.

[0089] As described above, the present invention also contemplates therapeutic methods in which naked anti-granulocyte antibody components are supplemented with immunoconjugate or fusion protein administration. In one variation, naked anti-granulocyte antibodies are administered with low-dose radiolabeled anti-granulocyte antibodies or fragments. As a second alternative, naked anti-granulocyte antibodies are administered with low-dose radiolabeled anti-granulocyte-cytokine immunoconjugates. As a third alternative, naked anti-granulocyte antibodies are administered with anti-granulocyte-cytokine immunoconjugates that are not radiolabeled. With regard to "low doses" of radiolabeled immunoconjugates, a preferable dosage is:

[0090] The anti-granulocyte antibodies, immunoconjugates, and fusion proteins of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions.

[0091] 1. Method of Treating CML using Naked Anti-NCA-90

SUMM DETD

[0092] A patient with CML is treated with IFN-alpha2b for six months, but demonstrates a slow progression into the accelerated phase, with marked increase in.

SUMM DETD

[0093] 2. Method of Treating CML using Combination Therapy Comprising Naked Anti-NCA-90 Antibody

SUMM DETD

[0094] A patient with CML is treated with IFN-alpha2b for six months, but demonstrates a slow progression into the accelerated phase, with marked increase in.

SUMM CLM

What is claimed is:

1. A method for treating chronic myelocytic leukemia (CML) in a patient, comprising administering to said patient a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one naked anti-granulocyte antibody.
2. The method of claim 1, wherein said anti-granulocyte antibody is an anti-NCA-90 antibody.
3. The method of claim 1, wherein said anti-granulocyte antibody is an anti-NCA-95 antibody.
4. The method of claim 1, wherein said anti-granulocyte antibody is selected from the group consisting of MN-2, MN-15, NP-1 and NP-2.
5. The method of claim 1, wherein said anti-granulocyte antibody is an anti-NCA-90 antibody.

SUMM DEDT

[0095] a patient, comprising administering to said patient a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one naked anti-granulocyte antibody, and an inducing agent, wherein said inducing agent induces expression of antigens which are minimally displayed on the surface of.

SUMM DEDT

[0096] 7. The method of claim 1, wherein said anti-granulocyte antibody is selected from the group consisting of subhuman primate antibody, murine monoclonal antibody, chimeric antibody, humanized antibody and human antibody.

SUMM DEDT

[0097] 18. The method of any of claim 1, wherein said therapeutic composition comprises two or more naked anti-granulocyte antibodies.

SUMM DEDT

[0098] L3 ANSWER 7 OF 14 USPAT/01

SUMM DEDT

[0099] . . . stroke, each of which may lead to neurodegeneration; lung diseases (e.g., ARDS); multiple myeloma; multiple sclerosis; myelogenous (e.g., AML and CML) and other leukemias; myopathies (e.g., muscle protein metabolism, esp. in sepsis); osteoporosis; Parkinson's disease; pain; pre-term labor; psoriasis; reperfusion injury; . . .

SUMM DEDT

[0100] . . . or intramuscularly for the treatment of rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, multiple myeloma, or myelogenous (e.g., AML and CML) and other leukemias. By way of example but not limitation, in a still further specific embodiment IL-1 inhibitors (e.g., preferably, . . .)

SUMM DEDT

[0101] the following TNF inhibitors: TNF binding proteins (soluble TNF receptor Type I and soluble TNF receptor Type II ("sTNFRs")), anti-TNF antibodies, granulocyte colony stimulating factor; thalidomide; BN 7303; teniposide; PCA 4248; nimesulide; paravix; rolapitant; RP 73401; peptide T; MDL . . .

SUMM DEDT

[0102] . . . interferon (e.g., alpha interferon, beta interferon, gamma interferon and consensus interferon) to treat multiple myeloma or myelogenous (e.g., AML and CML) and other leukemias.

SUMM DEDT

[0103] ANSWER 8 OF 14 USPAT/01

SUMM DEDT

[0104] Anti-class I Cell-Mediated Lympholysis (CML) Assay: Spleens are removed from BMT recipients and normal mice, red cells are lysed using ACK buffer, and a single . . . is used as culture supernatant, and will be

SUMM DEDT

PROCESSING COMPLETED FOR L4
L5 16 DUP REM L4 (6 DUPLICATES REMOVED)

=> d 1-16

| | | | |
|--|--|-------------|---|
| AN | ANSWER 1 OF 16 USPATFULL 2002:98691 USPATFULL | 15 | ANSWER 4 OF 16 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V. |
| TI | Method and kit for imaging and treating organs and tissues | AN | 2002184867 EMBASE |
| IN | Goldenberg, Milton D.; Menchik, NJ, UNITED STATES | TI | Bone marrow scintigraphy with $(99m)$ Tc labelled monoclonal anti-NCA 90 Fab fragment: A feasibility study and comparison of bone marrow uptake with $(99m)$ Tc labelled monoclonal anti-NCA 95 antigen-urocyte antibody. |
| PA | IMMUNOMEDICS, INC. (U.S. corporation) | AU | Dr. V. Ivancevic V.; Huic D.; Wotter A.; Munz D.L. |
| PI | US 200205294 | IC | Dr. V. Ivancevic V.; Clinic for Nuclear Medicine, University Hospital Charite, Humboldt University, Schumannstr, 20-21, D-10117 Berlin, Germany |
| AI | US 2001-2211 | REF: | velimir.ivancevic@charite.de |
| RLI | AI 2001205 (10) | ISSN: | Nuclear Medicine Communications, (2002) 23/3 (249-255). |
| DT | Division of Ser. No. US 198-110181, filed on 6 Jul 1998, PATENTED Continuation-in-part of Ser. No. US 1988-167077, filed on 11 Mar 1988, PATENTED Continuation of Ser. No. US 1985-751877, filed on 5 Jul 1985, | Ref: | 25 |
| UTILITY | PATENTED | CY | ISSN: 0143-3636 CODEN: NMDCD |
| FS | APPLICATION | DT | United Kingdom |
| LN.CNT | 1204 | FS | Journal; Article |
| INCL | INC1M: 604/522.000 | 023 | Nuclear Medicine |
| INCL | INC1S: 604/020.000; 424/001.490 | 025 | Hematology |
| NCL | NC1M: 604/522.000 | 037 | Drug Literature Index |
| NC1S: | 604/020.000; 424/001.490 | LA | English |
| IC | (7) | SL | English |
| ICM: A61N001-30 | | | |
| CODEN: A61B005-05; A61M031-00 | | | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | | | |
| L5 | ANSWER 2 OF 16 CAPLUS COPYRIGHT 2003 ACS | DUPLICATE 1 | |
| AN | 2002-215819 CAPLUS | | |
| DN | 137-348455 | | |
| TI | Imaging of low-grade bone infection with a technetium-99m labeled monoclonal anti-NCA-90 Fab' fragment in patients with previous joint surgery | | |
| AU | Ivaneciae, V.; Perka, C.; Haart, O.; Sandrock, D.; Munz, D. L. | | |
| CS | Humboldt University of Berlin, University Hospital Charite, Clinic for Nuclear Medicine, Berlin, 10117, Germany | | |
| SO | European Journal of Nuclear Medicine and Molecular Imaging (2002), 29(4), 547-551 | | |
| CODEN: EDNM6 | | | |
| PB | Springer-Verlag | | |
| DT | Journal | | |
| LA | English | | |
| RE.CNT | 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD | | |
| ALL CITATIONS AVAILABLE IN THE RE FORMAT | | | |
| L5 | ANSWER 3 OF 16 MEDLINE | | |
| AN | 2002233701 MEDLINE | | |
| DN | 2191989 PubMed ID: 11914895 | | |
| TI | Imaging of low-grade bone infection with a technetium-99m labelled monoclonal anti-NCA-90 Fab' fragment in patients with previous joint surgery. | | |
| CM | Erratum in: Eur J Nucl Med Mol Imaging 2002 Jun;29(6):835 | | |
| CM | Erratum in: Ivaneciae, V. (corrected to Ivancevic, V.) | | |
| AU | Ivaneciae, V.; Perka, C.; Haart, O.; Sandrock, D.; Munz D. L.; Ivaneciae, V. | | |
| CS | Clinic for Nuclear Medicine, University Hospital Charite, Humboldt University of Berlin, Schumannstrasse 20-21, 10117 Berlin, Germany.. | | |
| SO | Eur J Nucl Med Mol Imaging, (2002 Apr) 29 (4) 547-51. | | |
| DT | Journal code: 0110-0988. ISSN: 1519-7070. | | |
| DT | Federal Republic of Germany: Germany; Germany: Federal Republic of | | |
| DT | Journal; Article; (JOURNAL ARTICLE) | | |
| LA | English | | |
| FS | Priority Journals | | |
| L5 | ANSWER 6 OF 16 USPATFULL | | |
| AN | 2001-230931 USPATFULL | | |
| TI | Method and kit for imaging and treating organs and tissues | | |
| IN | Goldenberg, Milton David, Short Hills, NJ, United States | | |
| PA | Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation) | | |
| PI | US 6331175, B1 2001218 | | |
| AI | US 198-110181 19980106 (9) | | |
| RUL | Division of Ser. No. US 1992-866789, filed on 7 Apr 1992, now patented, Pat. No. US 5776093 Continuation-in-part of Ser. No. US 1988-167077, filed on 11 Mar 1988, now patented, Pat. No. US 5101827 Continuation of Ser. No. US 1985-751877, filed on 5 Jul 1985, now patented, Pat. No. US 4735310 | | |
| DT | Utility | | |
| FS | GRANTED | | |
| LN.CNT | 881 | | |
| INCL | INC1M: 604/522.000 | | |
| INCL | INC1S: 604/020.000; 424/001.490 | | |
| NCL | NC1M: 604/522.000 | | |
| NCL | NC1S: 424/001.490; 604/020.000 | | |
| IC | (7) | | |
| EXF | ICM: A61M025-00 | | |
| EXF | 600/436; 424/1-29; 424/1-45; 424/1-49; 424/9-34; 424/9-4; 424/9-71; 530/388-8; 530/388-85; 604/20; 604/21; 604/500; 604/522; 128/898 | | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | | | |

424/1, 424/1,49; 358/111; 324/307; 324/310; 604/20; 604/28; 604/49;
530/388,2; 530/399,8; 530/91,3; 600/410; 600/411; 600/420

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 13 OF 16 USPATFULL
AN 97-117409 USPATFULL
TI Method for imaging and treating organs and tissues
IN Goldenberg, Milton David, Short Hills, NJ, United States
PA Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)
PI US 5697902
AI US 1995-456909 19950601 (8)
RLI Continuation of Ser. No. US 1992-86678, filed on 7 Apr 1992 which is a
now patented. Part of Ser. No. US 1988-167077, filed on 11 Mar 1988.

1985-751877, filed on 5 Jul 1985, now patented. Pat. No. US 473510

Utility

FS Granted

LN CNT 913

INCL INCLM: 604/049,000

INCL NCLM: 604,021,000; 128/898,000

NCL NCIS: 128/888,000; 604/021,000

[6] IC ICH: A61M031-00

EXF 128/898; 604/28; 604/49; 604/21

L5 ANSWER 14 OF 16 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

AN 96341152 EMBASE 1996341152

TI Intussusception secondary to Meckel's diverticulum: Detection with Tc- 99m
monoclonal antibodies to granulocytes (Leukoscan.RTM.).

AU Barron, B.J.; Lanki, L.M.; Daniels, W.; Chopra, L.; Black, C.T.

CS Department of Radiology, University of Texas Medical School, 6431

Fannin, Houston, TX 77030, United States

SO Clinical Nuclear Medicine (1996) 21/11 (834-837).

ISSN: 0363-9762 CODEN: CNMEDK

CY United States

DT Journal

FS 007 Pediatrics and Pediatric Surgery

023 Nuclear Medicine

037 Drug Literature Index

048 Gastroenterology

LA English

SL English

L5 ANSWER 15 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

AN 1996-144035 BIOSIS 1996-144035

DN PREV199608716171

TI Comparative pharmacokinetics, dosimetry, and in-vivo stability of two
formulations of 99mTc-labeled anti-granulocyte antibody
fab', fragment (IMMU-M03, LeukoScan™).

AU Webster, William B.; Harwood, Steven H.; Carroll, Robert G.; Morrissey, Michael; Hakki, Sam

CS Bay Pines VA Med. Cent., Bay Pines, FL USA

SO Pharmacotherapy, (1996) Vol. 16, No. 1, pp. 131-132.

Meeting Info.: American College of Clinical Pharmacy 1996 Winter Practice
and Research Forum Monterey, California, USA February 11-14, 1996

ISSN: 0277-0084.

DT Conference

LA English

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

AN 1995-525470 BIOSIS 1995-525470

DN PREV199508339770

TI The diagnostic and clinical utility of 99mTc-labeled anti-

granulocyte antibody IMMU-M03 scan (Leukoscan)
in osteomyelitis compared to WBC scans.

AU Querner, R. W. (1); Daniska, Jeff; (USA), The Immunomedics Osteomyelitis

CS Clinical Study Group

(1) Univ. New Mexico, Albuquerque, NM USA

SO Abstracts of the Interscience Conference on Antimicrobial Agents and

Chemotherapy, (1995) Vol. 35, No. 0, pp. 77.

Meeting Info.: 35th Interscience Conference on Antimicrobial Agents and

Chemotherapy San Francisco, California, USA September 17-20, 1995

PT Conference

LA English

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

LN CNT 13

INCL INCLM: 604/049,000

INCL NCLM: 604,021,000; 128/898,000

NCL NCIS: 128/888,000; 604/021,000

[6] IC ICH: A61M031-00

EXF 128/898; 604/28; 604/49; 604/21

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

LN CNT 14

INCL INCLM: 604/049,000

INCL NCLM: 604,021,000; 128/898,000

NCL NCIS: 128/888,000; 604/021,000

[6] IC ICH: A61M031-00

EXF 128/898; 604/28; 604/49; 604/21

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

LN CNT 15

INCL INCLM: 604/049,000

INCL NCLM: 604,021,000; 128/898,000

NCL NCIS: 128/888,000; 604/021,000

[6] IC ICH: A61M031-00

EXF 128/898; 604/28; 604/49; 604/21

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

LN CNT 16

INCL INCLM: 604/049,000

INCL NCLM: 604,021,000; 128/898,000

NCL NCIS: 128/888,000; 604/021,000

[6] IC ICH: A61M031-00

EXF 128/898; 604/28; 604/49; 604/21

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

LN CNT 17

INCL INCLM: 604/049,000

INCL NCLM: 604,021,000; 128/898,000

NCL NCIS: 128/888,000; 604/021,000

[6] IC ICH: A61M031-00

EXF 128/898; 604/28; 604/49; 604/21

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

LN CNT 18

INCL INCLM: 604/049,000

INCL NCLM: 604,021,000; 128/898,000

NCL NCIS: 128/888,000; 604/021,000

[6] IC ICH: A61M031-00

EXF 128/898; 604/28; 604/49; 604/21

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

LN CNT 19

INCL INCLM: 604/049,000

INCL NCLM: 604,021,000; 128/898,000

NCL NCIS: 128/888,000; 604/021,000

[6] IC ICH: A61M031-00

EXF 128/898; 604/28; 604/49; 604/21

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

LN CNT 20

INCL INCLM: 604/049,000

INCL NCLM: 604,021,000; 128/898,000

NCL NCIS: 128/888,000; 604/021,000

[6] IC ICH: A61M031-00

EXF 128/898; 604/28; 604/49; 604/21

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

LN CNT 21

INCL INCLM: 604/049,000

INCL NCLM: 604,021,000; 128/898,000

NCL NCIS: 128/888,000; 604/021,000

[6] IC ICH: A61M031-00

EXF 128/898; 604/28; 604/49; 604/21

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

LN CNT 22

INCL INCLM: 604/049,000

INCL NCLM: 604,021,000; 128/898,000

NCL NCIS: 128/888,000; 604/021,000

[6] IC ICH: A61M031-00

EXF 128/898; 604/28; 604/49; 604/21

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

LN CNT 23

INCL INCLM: 604/049,000

INCL NCLM: 604,021,000; 128/898,000

NCL NCIS: 128/888,000; 604/021,000

[6] IC ICH: A61M031-00

EXF 128/898; 604/28; 604/49; 604/21

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

LN CNT 24

INCL INCLM: 604/049,000

INCL NCLM: 604,021,000; 128/898,000

NCL NCIS: 128/888,000; 604/021,000

[6] IC ICH: A61M031-00

EXF 128/898; 604/28; 604/49; 604/21

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

LN CNT 25

INCL INCLM: 604/049,000

INCL NCLM: 604,021,000; 128/898,000

NCL NCIS: 128/888,000; 604/021,000

[6] IC ICH: A61M031-00

EXF 128/898; 604/28; 604/49; 604/21

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

LN CNT 26

INCL INCLM: 604/049,000

INCL NCLM: 604,021,000; 128/898,000

NCL NCIS: 128/888,000; 604/021,000

[6] IC ICH: A61M031-00

EXF 128/898; 604/28; 604/49; 604/21

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

LN CNT 27

INCL INCLM: 604/049,000

INCL NCLM: 604,021,000; 128/898,000

NCL NCIS: 128/888,000; 604/021,000

[6] IC ICH: A61M031-00

EXF 128/898; 604/28; 604/49; 604/21

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

LN CNT 28

INCL INCLM: 604/049,000

INCL NCLM: 604,021,000; 128/898,000

NCL NCIS: 128/888,000; 604/021,000

[6] IC ICH: A61M031-00

EXF 128/898; 604/28; 604/49; 604/21

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

LN CNT 29

INCL INCLM: 604/049,000

INCL NCLM: 604,021,000; 128/898,000

NCL NCIS: 128/888,000; 604/021,000

[6] IC ICH: A61M031-00

EXF 128/898; 604/28; 604/49; 604/21

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

LN CNT 30

INCL INCLM: 604/049,000

INCL NCLM: 604,021,000; 128/898,000

NCL NCIS: 128/888,000; 604/021,000

[6] IC ICH: A61M031-00

EXF 128/898; 604/28; 604/49; 604/21

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

LN CNT 31

INCL INCLM: 604/049,000

INCL NCLM: 604,021,000; 128/898,000

NCL NCIS: 128/888,000; 604/021,000

[6] IC ICH: A61M031-00

EXF 128/898; 604/28; 604/49; 604/21

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

LN CNT 32

INCL INCLM: 604/049,000

INCL NCLM: 604,021,000; 128/898,000

NCL NCIS: 128/888,000; 604/021,000

[6] IC ICH: A61M031-00

EXF 128/898; 604/28; 604/49; 604/21

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

LN CNT 33

INCL INCLM: 604/049,000

INCL NCLM: 604,021,000; 128/898,000

NCL NCIS: 128/888,000; 604/021,000

[6] IC ICH: A61M031-00

EXF 128/898; 604/28; 604/49; 604/21

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

LN CNT 34

INCL INCLM: 604/049,000

INCL NCLM: 604,021,000; 128/898,000

NCL NCIS: 128/888,000; 604/021,000

L10 ANSWER 1 OF 2 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

TI [Immunoscintigraphy with 99mTc-labelled antigranulocyte monovalent antibody fragments: diagnostic features in a case of brain abscess]

AU MARCAUTI CON 99^MTC: ASPECTI DIAGNOSTICI IN UN CASO DI ASCESO CEREBRALE.

CS Dr. M. Di Montele, Via Alcide De Gasperi, 39, I-73100 Lecce, Italy

SO Rivista di Neuroradiologia, (1999) 12/5 (679-684).

Refs: 16

ISSN: 1120-9976 CODEN: RIVNEJ

CY Italy

DR Journal; Article

FS 008 Neurology and Neurosurgery

014 Radiology

023 Nuclear Medicine

026 Immunology, Serology and Transplantation

037 Drug Literature Index

LA Italian

SL English; Italian

L10 ANSWER 2 OF 2 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

AN 94276417 EMBASE

DN 1994-76417

TI Detection of soft-tissue infections and osteomyelitis using a technetium-99m-labelled anti-granulocyte monoclonal antibody fragment.

AU Becker W.; Bair J.; Behr T.; Repp R.; Streckenbach H.; Beck H.; Gramatzki M.; Wilschup M.J.; Goldenberg D.M.; Wolf F.

CS Dept. of Nuclear Medicine, University of Erlangen-Nuremberg, Krankenhausstrasse 12,D-91054 Erlangen, Germany

SO Journal of Nuclear Medicine, (1994) 35/9 (1436-1443).

ISSN: 0161-5505 CODEN: JNMEDQ

CY United States

DT Journal; Article

FS 023 Nuclear Medicine

026 Immunology, Serology and Transplantation

037 Drug Literature Index

LA English

SL English

=> d his

(FILE 'HOME' ENTERED AT 14:13:41 ON 12 FEB 2003)

FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, CAPLUS, EMBASE, USPAPFULL'

ENTERED AT 14:14:19 ON 12 FEB 2003

L1 17/3 S GRANULOCYTE (A) ANTIBODY

L2 17 S LI AND CML

L3 14 DUP REM L12 (3 DUPLICATES REMOVED)

L4 22 S LI AND MBL3

L5 16 DUP REM L4 (6 DUPLICATES REMOVED)

L6 293 S LI AND ADMINISTRAT?

L7 282 DUP REM L6 (11 DUPLICATES REMOVED)

L8 282 S L7 NOT PV=>2000

L9 234 S L7 NOT PV=>2000

L10 2 S L9 AND NCA (A) 90

L11 ANSWER 1 OF 10 MEDLINE

AN 92235524 PubMed ID: 8475680

DN 92235524

TI [Immunoscintigraphy for detection of inflammatory perioperative foci].

AU Immunazintigraphie zur Aufdeckung entzündlicher perioperativer Foci.

CS Kroiss A.; Sporn P.; Aunerger C.; Reil E.; Bock F.; Dintil K.; Neumayr A.

SO Institut für Nuklearmedizin, Krankenhaus Rudolfsstiftung, Wien.

CY ACTA MEDICA AUSTRIACA, (1993) 20 (1-2) 45-9.

ISSN: 7501997. ISSN: 0303-8173.

AU Journal code: 7501997.

SO Journal code: 7501997. ISSN: 0303-8173.

CY Austria

DT Journal; Article; (JOURNAL ARTICLE)

LA German

FS Priority Journals

EM 199305

ED Entered STN: 19930504

ED Last Updated on STN: 19970203

ED Entered Medline: 19930520

L11 ANSWER 2 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

AN 2000038864 EMBASE

TI [Immunoscintigraphy with 99mTc-labelled antigranulocyte monovalent antibody fragments: Diagnostic features in a case of brain abscess].

AU MARCAUTI CON 99^MTC: ASPECTI DIAGNOSTICI IN UN CASO DI ASCESO CEREBRALE.

CS Di Montele, Via Alcide De Gasperi, 39, I-73100 Lecce, Italy

SO Rivista di Neuroradiologia, (1999) 12/5 (679-684).

Refs: 16

ISSN: 1120-9976 CODEN: RIVNEJ

CY Italy

DT Journal; Article

FS 008 Neurology and Neurosurgery

014 Radiology

023 Nuclear Medicine

026 Immunology, Serology and Transplantation

037 Drug Literature Index

LA Italian

SL English; Italian

L11 ANSWER 3 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

AN 199947732 EMBASE

TI Photopenic lesions in bone marrow scintigraphy using technetium-99m labelled antigranulocyte antibody without known turnout.

AU Krause Th.; Reinhardt M.; Nitzsche E.; Moser E.

CS Th. Krause, Radiologische Klinik, Abteilung Nuklearmedizin, Hugstetter Strasse 55, D-79106 Freiburg, Germany. krausesth@ul.uni-freiburg.de

SO Nuklearmedizin, (1999) 38/3 (85-89).

Refs: 24

ISSN: 0029-5566 CODEN: NUMEL

CY Germany

SO 0029-5566

DT Journal; Article

FS 016 Cancer

LA 023 Nuclear Medicine

025 Hematology

026 Immunology, Serology and Transplantation

037 Drug Literature Index

SL English

ENGLISH; German

L11 ANSWER 4 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

AN 1998176729 EMBASE

TI 99Tcm) labelled chimeric human/mouse antigranulocyte antibody bone marrow scintigraphy: A preliminary clinical study.

AU Higuchi T.; Inoue T.; Sarwar M.; Oriuchi N.; Karasawa M.; Naruse T.

=> s 19 and nca

L11 10 L9 AND NCA

=> d 1-10

Yamanaka H.; Watanae T.; Chung J.-K.; Endo K.
CS K. Endo, Departments of Nuclear Medicine, Gunma University School of
Medicine, 3-339-22 Showamachi, Maebashi, Gunma 371, Japan
SO Nuclear Medicine Communications, (1998) 19/5 (463-474).
Refs: 22
ISSN: 0143-3636 CODEN: NMOCDC

CY United Kingdom
DT Journal; Article
SO United Kingdom; Article
FS 014 Radiology
016 Cancer
023 Nuclear Medicine
025 Hematology
037 Drug Literature Index

LA English
SL English

L11 ANSWER 5 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 9427617 EMBASE
DN 1994216417

TI Detection of soft-tissue infections and osteomyelitis using a technetium-
99m-labeled anti-granulocyte monoclonal antibody fragment.
AU Becker W.; Bair J.; Behr T.; Repp R.; Streckenbach H.; Beck H.; Gramatzki
M.; Winkel M.J.; Goldenberg D.M.; Wolf P.
CS Dept. of Nuclear Medicine, University of Erlangen-Nuremberg,
Krankenhausstrasse 12, D-91054 Erlangen, Germany
SO Journal of Nuclear Medicine, (1994) 35/9 (1436-1443).
ISSN: 0161-5505 CODEN: JNMEDQ

CY United States
DT Journal; Article
FS 023 Nuclear Medicine
026 Immunology, Serology and Transplantation
037 Drug Literature Index

LA English
SL English

L11 ANSWER 6 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 93040173 EMBASE
DN 1993040303

TI Iridium-192-F(ab')2-NCA 102 monoclonal antibody: In vitro study of
a specific agent for the detection of inflammatory foci.
AU Collet B.; Maros S.; Moisan J.; Le Cloirec J.; Moinereau M.; Almaitre E.;
Toujas L.; Bourguet P.
CS Serv. Immunologie/Medicine Nucléaire, CHUCC, Eugène Marquis, Rue de la
Bataille Flandre-Dunkerque, 35062 Rennes Cedex, France
SO Nuclear Medicine and Biology, (1993) 20/2 (175-182).
ISSN: 0833-2897 CODEN: NMIEBO

CY United Kingdom
DT Journal; Article
FS 009 Surgery
023 Nuclear Medicine
026 Immunology, Serology and Transplantation
037 Drug Literature Index

LA English
SL English

L11 ANSWER 7 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 92085939 EMBASE
DN 1992085939

TI The single late 99Tcm granulocyte antibody scan in
inflammatory diseases.
AU Becker W.S.; Saptogino A.; Wolf P.G.
CS Department of Nuclear Medicine of the Friedrich-Alexander University of
Erlangen-Nürnberg, Krankenhausstrasse 12, 8520 Erlangen, Germany
SO Nuclear Medicine Communications, (1992) 13/3 (186-192).
ISSN: 0143-3636 CODEN: NMOCDC

CY United Kingdom
DT Journal; Conference Article
FS 023 Nuclear Medicine
026 Immunology, Serology and Transplantation
037 Drug Literature Index

LA English
SL English

L11 ANSWER 8 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 8000602 EMBASE
DN 198900602

TI In vitro labelling of granulocytes using 123I-tagged anti-
granulocyte antibodies.
AU Sybold K.
CS Department of Nuclear Medicine, Kantonsspital, CH-5001 Aarau, Switzerland
SO Nuclear Medicine Communications, (1988) 9/10 (745-752).
ISSN: 0143-3636 CODEN: NMOCDC

CY United Kingdom
DT Journal
FS 008 Neurology and Neurosurgery
015 Chest Diseases, Thoracic Surgery and Tuberculosis
023 Nuclear Medicine
026 Immunology, Serology and Transplantation
033 Orthopedic Surgery
037 Drug Literature Index

LA English
SL English

L11 ANSWER 9 OF 10 USPATFULL
AN 9714738 USPATFULL
TI Detection of cardiovascular lesions
IN Goldenberg, David M., Short Hills, NJ, United States (U.S. corporation)
PA Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)
PI US 5633968
AI 1994-338100
RLI Continuation of Ser. No. US 1991-694977, filed on 6 May 1991, now
Patented, Pat. No. US 5364612

DT Utility
FS Granted

IN CNTR 1053
INCL INCLM: 424/001,490
INCLUS: 424/003,340
NCL NCLM: 424/001,490
NCLUS: 424/009,340
IC (6)
ICM: A61K051-10
ICS: A61B005-055
EXF 424/1,49; 424/1,53; 424/9,34; 424/179,1; 424/180,1; 424/182,1

L11 ANSWER 10 OF 10 USPATFULL
AN 9419668 USPATFULL
TI Detection of cardiovascular lesions
IN Goldenberg, David M., Short Hills, NJ, United States (U.S. corporation)
PA Immunomedics, Inc., Warren, NJ, United States (U.S. corporation)
PI US 5364612
AI US 1991-694977
DT Utility
FS Granted

IN CNTR 1163
INCL INCLM: 424/001,530
INCLUS: 424/001,490; 424/009,000; 424/136,100; 424/152,100; 424/153,100;
NCL NCLM: 424/001,530
NCLUS: 424/001,490; 424/009,341; 424/136,100; 424/152,100; 424/153,100;

IC 424/154.100; 424/172.100; 424/173.100; 530/391.300
[5] ICM: A61K039-025

EXF 424/1..; 424/9; 424/1..49; 424/1..53..530/396; 530/402; 530/409;
530/388.25; 530/388.7; 530/391.1; 530/391.3

=> d 8 ab

L11 ANSWER 8 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AB On the basis of previous work with various monoclonal antibodies (Mab) raised against carcinoembryonic antigen (CEA), the anti-CEA Mab 47 was identified which selectively reacted with a surface glycoprotein (95 kDa; NCA 95%) of normal human granulocytes. This new tracer was quality tested and radioiodinated with ^{123}I Mab 47 for clinical use according to established procedures. Extended *in vitro* studies revealed a high selectivity for granulocytes without inhibiting their *in vivo* use functions. *In vivo* cell binding to the granulocyte pool was completed very rapidly and remained unchanged over 24 h. For clinical use one dose consisting of 120 mcg of Mab was labelled with 4-5 mCi of ^{123}I . Clinical interest was mainly concentrated on cases of osteomyelitis, infected allografts and abdominal and brain abscesses. After injection of ^{123}I Mab 47, infectious lesions were usually seen after 3-5 h or could be excluded after 24 h. Because of high counting rates the image quality was excellent and single photon emission computerized tomography (SPECT) could be performed for an exact topographical localization of the lesions. No adverse reactions have been seen. It is concluded that there are distinct advantages of the new method compared with scanning of ^{111}In -labelled leucocytes. However, despite this and the low dose of antibodies administered, we recommend restriction of immunoscintigraphy of infectious lesions before a clinically relevant immunization can be excluded.

=> d ihb ab 8

L11 ANSWER 8 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

DOCUMENT NUMBER: 89000602 EMBASE

TITLE: 19800602

AUTHOR: In vivo labelling of granulocytes using ^{123}I -tagged anti-

CORPORATE SOURCE: granulocyte antibodies.

Seybold K. Department of Nuclear Medicine, Kantonsspital, CH-5001

Arbon, Switzerland

SOURCE: Nuclear Medicine Communications, (1988) 9/10 (745-752).

COUNTRY: ISBN 0143-3656 CODEN: NMDC

United Kingdom

DOCUMENT TYPE: Journal

FILE SEGMENT: 008 Neurology and Neurosurgery
015 Chest Diseases, Thoracic Surgery and Tuberculosis
023 Nuclear Medicine
025 Hematology
026 Immunology, Serology and Transplantation
033 Orthopedic Surgery
037 Drug Literature Index

LANGUAGE: English

SUMMARY LANGUAGE: English

AB On the basis of previous work with various monoclonal antibodies (Mab) raised against carcinoembryonic antigen (CEA), the anti-CEA Mab 47 was identified which selectively reacted with a surface glycoprotein (95 kDa; NCA 95%) of normal human granulocytes. This new tracer was quality tested and radioiodinated with ^{123}I (123I Mab 47) for clinical use according to established procedures. Extended *in vitro* studies revealed a high selectivity for granulocytes without inhibiting their vital functions. *In vivo* cell binding to the granulocyte pool was completed very

rapidly and remained unchanged over 24 h. For clinical use one dose consisting of 120 mcg of Mab was labelled with 4-5 mCi of ^{123}I . Clinical interest was mainly concentrated on cases of osteomyelitis, infected allografts and abdominal and brain abscesses. After injection of ^{123}I Mab 47, infectious lesions were usually seen after 3-5 h or could be excluded after 24 h. Because of high counting rates the image quality was excellent and single photon emission computerized tomography (SPECT) could be performed for an exact topographical localization of the lesions. No adverse reactions have been seen. It is concluded that there are distinct advantages of the new method compared with scanning of ^{111}In -labelled leucocytes. However, despite this and the low dose of antibodies administered, we recommend restriction of immunoscintigraphy of infectious lesions before a clinically relevant immunization can be excluded.

=> d his

(FILE 'HOME' ENTERED AT 14:13:41 ON 12 FEB 2003)

FILE 'MEDLINE', CANCERLIT, BIOSIS, CONFSCI, CARPLUS, EMBASE, USPATFULL', ENTERED AT 14:14:19 ON 12 FEB 2003

L1 1723 S GRANULOCYTE (A) ANTIBODY

L2 17 S LI AND CML

L3 14 DUP REM L2 (3 DUPLICATES REMOVED)

L4 22 S LI AND MN3

L5 16 DUP REM L4 (6 DUPLICATES REMOVED)

L6 293 S LI AND ADMINISTRAT?

L7 282 DUP REM L6 (11 DUPLICATES REMOVED)

L8 282 S 17 NOT Y=>2000

L9 234 S 17 NOT PY=>2000

L10 2 S 19 AND NCA (A) 90

L11 10 S 19 AND NCA

=> s cm1

L12 32001 CM1

=> s 112 and granulocyte

L13 3824 L12 AND GRANULOCYTE

=> s 113 and antibody?

L14 831 L13 AND ANTIBOD?

=> s 114 and nca?

L15 23 L14 AND NCA?

=> dup rem 115

PROCESSING COMPLETED FOR L15

L16 18 DUP REM L15 (5 DUPLICATES REMOVED)

=> d.1-18

L16 ANSWER 1 OF 18 USPATFULL
AN 2003:23733 USPATFULL
TI Polymerase kappa Compositions and methods therefor
IN Friedberg, Errol C., Dallas, TX, UNITED STATES
Fever, William J., Branford, CT, UNITED STATES
PA Board of Regents, The University of Texas System (U.S. corporation)
PI US 200301573 Al 20030123
AI US 2001-971101 Al 20011004 (9)
PRAT US 2000-2382899 20001004 (60)
DT 7012
FS APPLICATION
INCL INCL: 435/226.000

US 2000-230437P 20000906 (60)
 US 2000-251990P 20001008 (60)
 US 2000-251998P 20001205 (60)
 US 2000-251030P 20001205 (60)
 DT UTILITY
 FS APPLICATION
 INLN CNT 5666
 INCL INCL: 424/045.000
 INCL INCL: 424/078.300; 514/002.000
 NCL NCL: 424/045.000
 NCL NCL: 424/078.300; 514/002.000
 IC [71]
 ICM: A61K031-785
 ICS: A61K038-16; A61L009-04; A61K031-77
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 5 OF 18 USPATFULL
 AN 2002:315059 USPATFULL
 TI Compositions and methods for treatment of neoplastic disease
 IN Teman, David S., Pebble Beach, CA., UNITED STATES
 PI US 2002177551 Al 20021128
 AI US 2001-870759 Al 20010530 (9)
 PRAI US 2000-208128P 20000531 (60)
 DT UTILITY
 FS APPLICATION
 INLN CNT 17233
 INCL INCL: 514/012.000
 INCL INCL: 435/325.000; 530/350.000
 NCL NCL: 514/012.000
 NCL NCL: 435/325.000; 530/350.000
 IC [71]
 ICM: A61K031-7
 ICS: C12N005-06; C07K014-705
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 6 OF 18 USPATFULL
 AN 2002:280013 USPATFULL
 TI Gene differentially expressed in breast cancer, and encoded polypeptides
 IN Zadeerler, Maurice, Pittsford, NY, UNITED STATES
 Evans, Elizabeth E., Rochester, NY, UNITED STATES
 Borrelli, Melinda A., Pittsford, NY, UNITED STATES
 PI US 2002155447 Al 20021024
 AI US 2001-824787 Al 200104 (9)
 PRAI US 2000-194463P 20000404 (60)
 DT UTILITY
 FS APPLICATION
 INLN CNT 8851
 INCL INCL: 435/006.000
 INCL INCL: 435/007.200; 435/069.100; 435/226.000; 435/320.100; 435/325.000;
 NCL NCL: 435/023.200
 NCL NCL: 435/006.000
 NCL NCL: 435/007.200; 435/069.100; 435/226.000; 435/320.100; 435/325.000;
 IC [71]
 ICM: C12B001-68
 ICS: C01N033-574; C07H021-04; C12N009-64; C12P021-02; C12N005-06
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 7 OF 18 USPATFULL
 AN 2002:272939 USPATFULL
 TI PEI: DNA vector formulations for in vitro and in vivo gene delivery
 IN Cristiano, Richard J., Pearland, TX, UNITED STATES
 Yamashita, Motoyuki, Kochi City, JAPAN
 PA Board of Regents, The University of Texas System (U.S. corporation)
 PI US 200151060 Al 20021017
 AI US 2001-962922 Al 20010925 (9)
 PRAI US 2000-235237P 20000925 (60)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 8 OF 18 USPATFULL
 AN 2002:272940 USPATFULL
 TI PEI: DNA vector formulations for in vitro and in vivo gene delivery
 IN Perez-Soler, Roman, New York, NY, UNITED STATES
 PI US 2002187105 Al 20021212

| | | | |
|---|-----------------|---|----------------|
| US 2000-235635P | 20000926 (60) | US 2000-225758P | 20000814 (60) |
| DT UTILITY | | US 2000-220963P | 20000726 (60) |
| FS APPLICATION | | US 2000-217496P | 20000711 (60) |
| LN_CNT 7002 | | US 2000-225447P | 20000814 (60) |
| INCL INCLM: 435/455.000 | | US 2000-21829P | 20000714 (60) |
| INCL INCIS: 514/044.000; 424/486.000 | | US 2000-223757P | 20000814 (60) |
| NCL NCLM: 435/455.000 | | US 2000-226868P | 20000822 (60) |
| NCIS: 514/044.000; 424/486.000 | | US 2000-216647P | 20000707 (60) |
| IC [7] | | US 2000-225267P | 20000814 (60) |
| ICM: A61K048-00 | | US 2000-216880P | 20000707 (60) |
| ICGS: C12N015-87; A61K009-14 | | US 2000-225270P | 20000814 (60) |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | | US 2000-221865P | 200011208 (60) |
| L16 ANSWER 8 OF 18 USPATFULL | | US 2000-23583P | 20000927 (60) |
| AN 2002-231760 USPATFULL | | US 2000-234224P | 20000921 (60) |
| TI 55054, a novel human metalloprotease and uses therefor | | US 2000-234422P | 20000921 (60) |
| IN Kappeller-Jibermann, Rosana, Chestnut Hill, MA, UNITED STATES | | US 2000-228924P | 20000830 (60) |
| PA Millennium Pharmaceutical, Inc., Cambridge, MA, UNITED STATES, 02139 | | US 2000-224518P | 20000929 (60) |
| (U.S. corporation) | | US 2000-22635P | 20000929 (60) |
| PI US 2002137713 | AI 20020926 | US 2000-224519P | 20000929 (60) |
| AI US 2001-963290 | AI 20010225 (9) | US 2000-220965P | 20000776 (60) |
| PRAT US 2000-235055P | 20000925 (60) | US 2000-241809P | 20001020 (60) |
| DT UTILITY | | US 2000-249299P | 20001117 (60) |
| FS APPLICATION | | US 2000-236327P | 20000929 (60) |
| LN_CNT 4034 | | US 2000-241785P | 20001120 (60) |
| INCL INCLM: 514/044.000 | | US 2000-244617P | 200011101 (60) |
| INCL INCIS: 435/455.000; 536/023.200 | | US 2000-224534P | 20000924 (60) |
| NCL NCIS: 514/044.000 | | US 2000-236368P | 20000929 (60) |
| IC [7] | | US 2000-22937P | 20000929 (60) |
| ICM: A61K048-00 | | US 2000-231413P | 20000905 (60) |
| ICGS: C07H021-04; C12N015-87 | | US 2000-229509P | 20000905 (60) |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | | US 2000-23497P | 20000925 (60) |
| L16 ANSWER 9 OF 18 USPATFULL | | US 2000-229343P | 20000901 (60) |
| AN 2002-191201 USPATFULL | | US 2000-229345P | 20000901 (60) |
| TI USES of monoclonal antibody 8H9 | | US 2000-22927P | 20000911 (60) |
| IN Cheung, Nai-Kong V., Purchase, NY, UNITED STATES | | US 2000-23537P | 20000929 (60) |
| PI US 200210264 | AI 20020801 (9) | US 2000-237039P | 20001002 (60) |
| AI US 2001-982645 | AI 20011018 (9) | US 2000-237038P | 20001002 (60) |
| PRAT US 2000-241344P | 20000918 (60) | US 2000-236370P | 20000929 (60) |
| DT UTILITY | | US 2000-236802P | 20001002 (60) |
| FS APPLICATION | | US 2000-237040P | 20001002 (60) |
| LN_CNT 6128 | | US 2000-240960P | 20001020 (60) |
| INCL INCLM: 424/155.00 | | US 2000-239935P | 20001013 (60) |
| NCL NCIS: 424/155.100; 530/389.100; 435/326.000 | | DT UTILITY | |
| IC [7] | | FS APPLICATION | |
| ICM: A61K039-395 | | LN_CNT 20931 | |
| ICGS: C07K15/45; C12N005-06 | | INCL INCLM: 514/012.000 | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | | INCL INCIS: 435/059.000; 435/325.000; 435/320.100; 435/183.000; 536/023.100 | |
| L16 ANSWER 10 OF 18 USPATFULL | | NCL NCIS: 435/059.100; 435/325.000; 435/320.100; 435/183.000; 536/023.100 | |
| AN 2002-165193 USPATFULL | | IC [7] | |
| TI Nucleic acids, proteins, and antibodies | | ICM: A61K038-17 | |
| IN Rosen, Craig A., Laytonsville, MD, UNITED STATES | | ICGS: C07H021-04; C12N009-00; C12P021-02; C12N005-06 | |
| Ruben, Steven M., Olney, MD, UNITED STATES | | CAS INDEXING IS AVAILABLE FOR THIS PATENT. | |
| Barash, Steven C., Rockville, MD, UNITED STATES | | L16 ANSWER 11 OF 18 USPATFULL | |
| PI US 2002086822 | AI 20020704 | AN 2002-165192 USPATFULL | |
| AI US 2001-764886 | AI 20010117 (9) | TI Nucleic acids, proteins, and antibodies | |
| PRAT US 2000-179055P | 20000131 (60) | IN Rosen, Craig A., Laytonsville, MD, UNITED STATES | |
| US 2000-180628P | 20000204 (60) | Ruben, Steven M., Olney, MD, UNITED STATES | |
| US 2000-214886P | 20000628 (60) | Barash, Steven C., Rockville, MD, UNITED STATES | |
| US 2000-217487P | 20000711 (60) | PI US 2002086821 | |
| | | AI 20020704 | |

AI US 2001-764881 **AI** 20010117 (9)
PRAI US 2000-179065P **AI** 20000131 (60)
DT **UTILITY**
FS **APPLICATION**
LN.CNT 27531
INCL INCIM: 514/012.000
INCUS: 536/023.100; 435/069.100; 435/183.000; 435/320.100; 435/325.000
NCL NCLM: 536/023.100; 435/069.100; 435/183.000; 435/320.100; 435/325.000
IC [71] ICM: A61K038-17
IC5: C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 **ANSWER 12 OF 18 USPATFULL**
AN 2002:154712 USPATFULL
TI Nucleic acids, and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Barash, Steven C., Rockville, MD, UNITED STATES
PI US 2002008330 **AI** 20020704
AI US 2001-764893 **AI** 20010117 (9)
PRAI US 2000-179065P **AI** 20000131 (60)
US 2000-150620P **AI** 20000204 (60)
US 2000-214886P **AI** 20000628 (60)
US 2000-217487P **AI** 20000711 (60)
US 2000-225758P **AI** 20000814 (60)
US 2000-220963P **AI** 20000726 (60)
US 2000-217496P **AI** 20000711 (60)
US 2000-225447P **AI** 20000814 (60)
US 2000-218290P **AI** 20000714 (60)
US 2000-225757P **AI** 20000814 (60)
US 2000-216647P **AI** 20000707 (60)
US 2000-226868P **AI** 20000822 (60)
US 2000-215859P **AI** 20000927 (60)
US 2000-225341P **AI** 20000921 (60)
US 2000-224223P **AI** 20000921 (60)
US 2000-228942P **AI** 20000830 (60)
US 2000-224588P **AI** 20000834 (60)
US 2000-236365P **AI** 20000929 (60)
US 2000-224519P **AI** 20000834 (60)
US 2000-220964P **AI** 20000756 (60)
US 2000-221089P **AI** 20000920 (60)
US 2000-249299P **AI** 20001117 (60)
US 2000-236327P **AI** 20000929 (60)
US 2000-241785P **AI** 20000101 (60)
US 2000-6117P **AI** 20001101 (60)
US 2000-225268P **AI** 20000834 (60)
US 2000-236368P **AI** 20000929 (60)
US 2000-251856P **AI** 20001208 (60)
US 2000-231858P **AI** 20000834 (60)
US 2000-236344P **AI** 20000901 (60)
US 2000-224997P **AI** 20000925 (60)
US 2000-229343P **AI** 20000901 (60)
US 2000-229345P **AI** 20000901 (60)
US 2000-229287P **AI** 20000901 (60)
US 2000-229513P **AI** 20000905 (60)
US 2000-221413P **AI** 20000908 (60)
US 2000-229509P **AI** 20000905 (60)
US 2000-236367P **AI** 20000929 (60)
US 2000-237039P **AI** 20001002 (60)

L16 **ANSWER 13 OF 18 USPATFULL**
AN 2002:126343 USPATFULL
TI Genes that regulate hematopoietic blood forming stem cells and uses thereof
IN Lemischka, Inhor, Princeton, NJ, UNITED STATES
 More, Kateri, Princeton, NJ, UNITED STATES
PI US 2002064855 **AI** 20020530
AI US 2001-769919 **AI** 20010221 (9)
PRAI WO 1999-US19052 19990230
DT **UTILITY**
FS **APPLICATION**
LN.CNT 6639
INCL INCIM: 435/226.000
NCL INCUS: 435/059.100; 435/372.000; 435/320.100; 536/023.200; 435/189.000
IC [71] ICM: C12N009-02
IC5: C12N03/64; C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 **ANSWER 14 OF 18 USPATFULL**
AN 2002:37315 USPATFULL
TI Immunotherapy for chronic myelocytic leukemia
IN Goldemberg, David M., Menidham, NJ, UNITED STATES
 Hansen, Hans J., Sidell, ILA, UNITED STATES
PI US 2002022031 **AI** 20020221
AI US 2001-924103 **AI** 20010808 (9)
PRAI US 2000-223698P **AI** 20000808 (60)

L16 **ANSWER 15 OF 18 USPATFULL**
AN 2002:332463 USPATFULL
TI Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MIF-1) (Ckappa-8/MIF-3)
IN Li, Haodong, Gaithersburg, MD, United States
 Ruben, Steven M., Olney, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

| | | | |
|---------|--|---------------|---------------|
| PI | US 6495129 | BL | 20021217 |
| AI | US 6869693 | | |
| RLI | Continuation of Ser. No. US 2000-51013, filed on 15 May 2000 | | |
| | Continuation-in-part of Ser. No. US 1999-34981, filed on 17 Jun 1999 | | |
| | Continuation of Ser. No. US 1997-941020, filed on 30 Sep 1997, now abandoned | | |
| | Continuation-in-part of Ser. No. US 1996-72273, filed on 30 Sep 1995, now abandoned | | |
| | Continuation-in-part of Ser. No. US 1996-72273, filed on 30 Sep 1995, now abandoned | | |
| PRAI | Continuation-in-part of Ser. No. US 1995-468775, filed on 6 Jun 1995, now abandoned | | |
| | Continuation-in-part of Ser. No. US 1995-46582, filed on 6 Jun 1995, now abandoned | | |
| | Continuation-in-part of Ser. No. US 1995-44881, filed on 5 May 1995, now abandoned | | |
| | Continuation-in-part of Ser. No. US 1995-46775, filed on 5 May 1995, now abandoned | | |
| | Continuation-in-part of Ser. No. US 46881 Continuation of Ser. No. US 46881 Continuation-in-part of Ser. No. US 1994-20839, filed on 8 Mar 1994, now patented, Pat. No. US 5504003 Continuation of Ser. No. US 46881 Continuation-in-part of Ser. No. US 208339 Continuation-in-part of Ser. No. US 2000-2126580 | | |
| | 20000619 (60) | | |
| | 20000613 (60) | | |
| | US 2000-2114582 | | |
| | 20000424 (60) | | |
| | US 2000-1890489 | | |
| | 20000314 (60) | | |
| | US 1999-1720630 | | |
| | 19991223 (60) | | |
| | US 1999-1640599 | | |
| | 19991108 (60) | | |
| | US 1999-159362P | | |
| | 19991014 (60) | | |
| DT | Utility | | |
| FS | GRANTED | | |
| LN. CNT | 14198 | | |
| INCL | INC1M: 424/085.100 | | |
| | INC1S: 424/085.000; 514/002.000; 514/008.000; 514/012.000 | | |
| NCL | NCLM: 424/085.100 | | |
| | NCLS: 514/002.000; 514/008.000; 514/012.000 | | |
| IC | {71} | | |
| EXF | ICM: A61K009-19 | | |
| | 424/85.1; 424/885; 514/2; 514/8; 514/12 | | |
| AN | ANSWER 16 OF 18 USPATFULL | | |
| TI | 2003-231143 USPATFULL | | |
| IN | Arrays for identifying agents which mimic or inhibit the activity of interferons | | |
| | Silverman, Robert H., Beachwood, OH, United States | | |
| | Williams, Bryan R. G., Cleveland, OH, United States | | |
| PA | Der Sandy, Cleveland, OH, United States | | |
| | The Cleveland Clinic Foundation, Cleveland, OH, United States (U.S. corporation) | | |
| PT | US 6331396 | B1 | 20011218 |
| | US 1999-405438 | | 19990923 (9) |
| PRAI | US 1998-101497P | | 19980923 (60) |
| DT | Utility | | |
| FS | GRANTED | | |
| LN. CNT | 9639 | | |
| INCL | INC1M: 435/006.000 | | |
| | INC1S: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310. | | |
| NCL | NCLM: 435/006.000 | | |
| | NCLS: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310 | | |
| IC | {17} | | |
| | ICM: C12Q001-68 | | |
| | IC1S: C12M001-36; C07H021-04 | | |
| EXF | 435/16; 435/287.2; 536/23.1; 536/24.31; 536/23.52 | | |
| CAS | INDEXING IS AVAILABLE FOR THIS PATENT. | | |
| L16 | ANSWER 17 OF 18 MEDLINE | | DUPLICATE 1. |
| AN | 91187141 | MEDLINE | |
| DN | 91187141 | PUBLISHED ID: | 2011210 |

revealed that the expression of various markers could change in a different way during the differentiation of cells from myeloblasts to mature granulocytes.

L16 ANSWER 18 OF 18 MEDLINE
ACCESSION NUMBER: 82141196 MEDLINE
DOCUMENT NUMBER: 82141196 Published ID: 6949877
TITLE: Clinical evaluation of NCA in patients with
Warren B; Garrison G; Ruden U; Hammarstrom S
INTERNATIONAL JOURNAL OF CANCER, (1982 Feb 15) 29 (2)
133-7.
Journal code: 004124. ISSN: 0020-7136.
PUB. COUNTRY: Denmark
DOCUMENT TYPE: Journal, Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Primary Journals
ENTRY MONTH: 198205
ENTRY DATE: Entered STM: 19900317
Last Updated on STM: 19900317
Entered Medline: 19820512

AB NCA, a normal colon and granulocyte antigen, which has been found in large amounts in myelocytes and metamyelocytes and in smaller amounts in neutrophil granulocytes, was studied in 50 CML patients in various stages of the disease. Radiimmunoassay was used to demonstrate NCA in serum. Untreated CML patients had a mean level of 732 micrograms NCA/l, poorly controlled patients 421 micrograms/l and well-controlled patients 160 mu/l. These values differ significantly from the mean of healthy persons, which was 71 micrograms NCA/l. The serum NCA levels were related to the number of maturing myeloid cells in blood, and to the clinical course in the chronic phase of CML. In blast crisis low values with a mean of 109 micrograms NCA/l was found. Patients with ANLL had a low mean level, 50 micrograms/l. Low levels of NCA could not be attributed to antibodies to NCA.
NCA is a normal myeloid differentiation antigen. Despite this, its occurrence in serum in leukemic patients differs from normal. This probably has to do with the abnormal amount as well as the release of NCA by leukemic maturing myeloid cells.

=> d his

(FILE 'HOME' ENTERED AT 14:13:41 ON 12 FEB 2003)

FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCII, CAPLUS, EMBASE, USPATFULL'
ENTERED AT 14:14:19 ON 12 FEB 2003
L1 1723 S GRANULOCYTE (A) ANTIBODY
L2 17 S L1 AND CML
L3 14 DUP REM L2 (3 DUPLICATES REMOVED)
L4 22 S L1 AND MN3
L5 16 DUP REM L4 (6 DUPLICATES REMOVED)
L6 293 S L1 AND ADMINISTRAT?
L7 282 DUP REM L6 (11 DUPLICATES REMOVED)
L8 282 S L7 NOT Y=>2000
L9 234 S L7 NOT P=>2000
L10 2 S L9 AND NCA (A) 90
L11 10 S L9 AND NCA
L12 32001 S CML
L13 3224 S L12 AND GRANULOCYTE
L14 831 S L13 AND ANTIBOD?
L15 23 S L14 AND NCA?
L16 18 DUP REM L15 (5 DUPLICATES REMOVED)

=> s 114 and humaniz?

L17 204 L14 AND HUMANIZ?

=> s 117 and cd33

L18 24 L17 AND CD33

=> dup rem 118
PROCESSING COMPLETED FOR L18
L19 24 DUP REM L18 (0 DUPLICATES REMOVED)

=> d 1-24

L19 ANSWER 1 OF 24 USPATFULL
2003:38351 USPATFULL
AN Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
IN Holtzman, Douglas A.; Jamaica Plain, MA, UNITED STATES
PI Barnes, Thomas M.; Brookline, MA, UNITED STATES
AI US 2003021998 Ser. No. US 1998-183175, filed on 30 Oct 1998, ABANDONED Continuation-in-part of Ser. No. US 2000-599596, filed on 22 Jun 2000, ABANDONED Division of Ser. No. US 1998-223094, filed on 30 Dec 1998, ABANDONED Continuation-in-part of Ser. No. US 2000-514010, filed on 25 Feb 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-259388, filed on 26 Feb 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-516745, filed on 1 Mar 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-597933, filed on 30 Dec 1998, ABANDONED Continuation-in-part of Ser. No. US 1999-474071, filed on 29 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-33633, filed on 18 Jun 1999, PENDING Continuation-in-part of Ser. No. US 2000-630334, filed on 31 Jul 2000, PENDING Continuation-in-part of Ser. No. US 1999-305164, filed on 30 Jul 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-665666, filed on 20 Sep 2000, PENDING Continuation-in-part of Ser. No. US 1999-399723, filed on 20 Sep 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-667751, filed on 21 Sep 2000, PENDING Continuation-in-part of Ser. No. US 1999-409634, filed on 30 Sep 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-572002, filed on 15 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-312359, filed on 14 May 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-606555, filed on 29 Jun 2000, PENDING Continuation-in-part of Ser. No. US 1999-342687, filed on 29 Jun 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-603117, filed on 29 Jun 2000, PENDING Continuation-in-part of Ser. No. US 1999-345464, filed on 30 Jun 1999, ABANDONED US 1999-122458P, 19990301 (60)

PRAT DT
FS APPLICATION

LN CNT 2222

INCL INCL INCL: 536/023.100

NCL NCL: 536/023.100

IC [71] ICM: C07H021-02

ICS: C07H021-04

L19 ANSWER 2 OF 24 USPATFULL
AN 2003:34162 USPATFULL
TI Gene therapy of diseases associated with the immune system, using a cell-specific active compound which is regulated by the cell cycle
IN Seelack, Hans-Herlind, Marburg, GERMANY, FEDERAL REPUBLIC OF
Muller, Rolf, Marburg, GERMANY, FEDERAL REPUBLIC OF

PI US 2003018005 A1 20030123
 AI US 2002-112953 A1 20020402 (10)
 RLI Continuation of Ser. No. US 1997-793109, filed on 25 Apr 1997, GRANTED,
 Pat. No. US 6384202
 PRAI GB 1994-17366 19940826
 DE 1995-15524720 19950329
 DT UTILITY
 FS APPLICATION
 LN CNT 3163
 INCL INCLM: 514/044.000
 INCLS: 536/023.200; 536/023.500
 NCL NCIM: 514/044.000
 NCIS: 536/023.200; 536/023.500
 IC [71] ICM: A61K9/8-00
 ICS: C07H021-04
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 3 OF 24 USPATFULL
 AN 2002-315059 USPATFULL
 TI Compositions and methods for treatment of neoplastic disease
 IN Terman, David S., Pebble Beach, CA, UNITED STATES
 PI US 2002177551 A1 20021128
 AI US 2001-87059 A1 20010530 (9)
 DT US 2000-208128P 20000531 (60)
 UTILITY
 FS APPLICATION
 LN CNT 17323
 INCL INCLM: 514/012.000
 INCLS: 435/325.000; 530/350.000
 NCL NCIM: 514/012.000
 NCIS: 435/325.000; 530/350.000
 IC [71] ICM: A61K9/17
 ICS: C12N005-06; C07K014-705
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 4 OF 24 USPATFULL
 AN 2002-30110 USPATFULL
 TI Hematopoietic growth factor inducible neuropeptide-1 gene
 IN Rameshwar, Praneela, Maplewood, NJ, UNITED STATES
 PA University of Medicine & Dentistry of New Jersey (2)
 PI US 2002166653 A1 20021114
 AI US 2001-39272 A1 20011020 (10)
 PRAI US 2000-241881P 20001020 (60)
 DT UTILITY
 FS APPLICATION
 LN CNT 3139
 INCL INCLM: 435/006.000
 INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
 NCL NCIM: 435/006.000
 NCIS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
 IC [71] ICM: C12N001-68
 ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-705
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 5 OF 24 USPATFULL
 AN 2002-213436 USPATFULL
 TI Restore cancer-suppressing functions to neoplastic cells through DNA
 IN Rubinfeld, Joseph, Danville, CA, UNITED STATES
 Chang, Lucy, San Mateo, CA, UNITED STATES
 DiMartino, Jorge, San Carlos, CA, UNITED STATES

PI US 2002114809 A1 20020822
 AI US 2001-799483 A1 20010221 (9)
 RLI UTILITY
 DT APPLICATION
 FS
 LN CNT 1466
 INCL INCLM: 424/155.100
 INCLS: 424/277.100; 424/649.000; 514/254.070; 514/269.000; 514/283.000;
 NCL NCIM: 514/171.000; 514/183.000; 514/027.000; 514/034.000; 514/049.000;
 NCIS: 514/171.000; 514/183.000; 514/027.000; 514/034.000; 514/049.000;
 IC [71] ICM: A61K019-00
 ICS: A61K019-395; A61K031-57; A61K031-495
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 6 OF 24 USPATFULL
 AN 2002-191201 USPATFULL
 TI Uses of monoclonal antibody 8H9
 IN Cheung, Nai-Kong V., Purchase, NY, UNITED STATES
 PI US 2002102264 A1 20020801
 AI US 2001-98645 A1 20010108 (9)
 PRAI US 2000-241344P 200001018 (60)
 DT UTILITY
 FS APPLICATION
 LN CNT 6128
 INCL INCLM: 424/155.100
 INCLS: 424/178.100; 530/389.100; 435/326.000
 NCL NCIM: 424/155.100
 NCIS: 424/178.100; 530/389.100; 435/326.000
 IC [71] ICM: A61K019-95
 ICS: C07K016-06; C12N005-06
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 7 OF 24 USPATFULL
 AN 2002-126888 USPATFULL
 TI 18221, a novel dual specificity phosphatase and uses thereof
 IN Meyers, Rachel A., Newton, MA, UNITED STATES
 PI US 2002065406 A1 20020530
 AI US 2001-815419 A1 20010322 (9)
 PRAI US 2000-191850P 20000324 (60)
 DT UTILITY
 FS APPLICATION
 LN CNT 5161
 INCL INCLM: 536/023.100
 INCLS: 435/006.000; 435/196.000
 NCL NCIM: 536/023.100
 NCIS: 435/006.000; 435/196.000
 IC [71] ICM: C07H021-02
 ICS: C07H021-04; C12N001-68; C12N009-16
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 8 OF 24 USPATFULL
 AN 2002-70194 USPATFULL
 TI Immunotherapy of malignant and autoimmune disorders in domestic animals
 IN Goldenberg, David M., Mendham, NJ, UNITED STATES
 PI US 2002041847 A1 20020411
 AI US 2001-921290 A1 20010803 (9)
 RLI Continuation-in-part of Ser. No. US 1998-38995, filed on 12 Mar 1998,
 GRANTED, Pat. No. US 6144982 Continuation-in-part of Ser. No. US 1999-307816, filed on 10 May 1999, GRANTED, Pat. No. US 6306393
 DT UTILITY

FS APPLICATION
LN CNT 1783
INCL INCM: 424/001.490
INCL INCM: 424/178.100; 424/154.100
NCL NCLM: 424/001.490
NCL NCLM: 424/178.100; 424/154.100
IC [7] ICM: A61K039-395
IC ICS: A61K051-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 9 OF 24 USPATFULL
AN 2002:60972 USPATFULL
TI 38692 and 21117, novel dual specificity phosphatase molecules and uses
therefor
IN Meyers, Rachel A., Newton, MA, UNITED STATES
PI US 2002034807 Al 20020321
AI US 2001-816494 Al 20010323 (9)
PRAI US 2000-191858P DT 20000324 (60)
Utility
FS APPLICATION
LN CNT 5760
INCL INCM: 435/196.000
INCL INCM: 435/006.000; 435/007.100; 435/069.100; 435/325.000; 536/023.200;
NCL NCLM: 435/196.000
NCL NCLM: 435/006.000; 435/007.100; 435/069.100; 435/325.000; 536/023.200;
IC [7] ICM: C12N009-16
IN Immunotherapy for chronic myelocytic leukemia
Hansen, Hans J., Sidell, LK, UNITED STATES
PI US 2002022031 Al 20020221
AI US 2001-924103 Al 20010508 (9)
PRAI US 2000-223698P DT 20000808 (60)
Utility
FS APPLICATION
LN CNT 1133
INCL INCM: 424/155.100
NCL NCLM: 424/155.100
IC [7] ICM: A61K039-395
IC ICS: A61K051-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 10 OF 24 USPATFULL
AN 2002:37315 USPATFULL
TI Goldenberg, David M., Mendham, NJ, UNITED STATES
Hansen, Hans J., Sidell, LK, UNITED STATES
PI US 2002022031 Al 20020221
AI US 2001-924103 Al 20010508 (9)
PRAI US 2000-223698P DT 20000808 (60)
Utility
FS APPLICATION
LN CNT 1133
INCL INCM: 424/155.100
NCL NCLM: 424/155.100
IC [7] ICM: A61K039-395
IC ICS: A61K051-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 11 OF 24 USPATFULL
AN 2002:33197 USPATFULL
TI Assay to detect a binding partner
Christopher, Richard Ian, Sydney, AUSTRALIA
Dos Remedios, Cristobal Guillermo, Sydney, AUSTRALIA
PI US 2002019018 Al 20020214
AI US 2001-88959 Al 20010625 (9)
RLI Continuation of Ser. No. WO 1999-AU1156, filed on 23 Dec 1999, UNKNOWN
PRAI AU 1998-7216 19981223
AU 1999-425 19990518
DT Utility
FS APPLICATION
LN CNT 2701
INCL INCM: 435/007.230

FS APPLICATION
LN CNT 1783
INCL INCM: 435/007.230
NCL NCLM: GOIN033-574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 12 OF 24 USPATFULL
AN 2002:332463 USPATFULL
TI Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MIF-1) (Cheta-8/MIF-1)
IN Li, Haodong, Gaithersburg, MD, United States
Ruben, Steven M., Olney, MD, United States
Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6495129 B1 20021217
US 6495129 B1 20001013 (9)
RRI Continuation of Ser. No. US 2000-57103, filed on 15 May 2000
Continuation-in-Part of Ser. No. US 1999-33491, filed on 17 Jun 1999
Continuation of Ser. No. US 1997-941020, filed on 30 Sep 1997, now abandoned
Continuation-in-Part of Ser. No. US 1996-722723, filed on 30 Sep 1996, now abandoned
Continuation-in-Part of Ser. No. US 1996-722719, filed on 30 Sep 1996, now patented, Pat. No. US 601606
Continuation-in-Part of Ser. No. US 1995-468775, filed on 6 Jun 1995, now abandoned
Continuation-in-Part of Ser. No. US 1995-465682, filed on 6 Jun 1995, now abandoned
Continuation-in-Part of Ser. No. US 1995-446881, filed on 5 May 1995, now abandoned
Continuation-in-Part of Ser. No. US 468775, Continuation-in-Part of Ser. No. US 465682
Continuation-in-Part of Ser. No. US 446881 Continuation-in-Part of Ser. No. US 1994-20339, filed on 8 Mar 1994, now patented, Pat. No. US 5504003 Continuation of Ser. No. US 44881 Continuation-in-Part of Ser. No. US 208339 Continuation-in-Part of Ser. No. US 2000-212658P 20000613 (60)
PRAI US 2000-211458P 20000424 (60)
US 2000-19112P 20000314 (60)
US 1999-172063P 19991223 (60)
US 1999-164059P 19991108 (60)
US 1999-159362P 19991014 (60)
DT Utility
FS GRANTED
LN CNT 14198
INCL INCM: 424/095.100
INCL INCM: 424/095.000; 514/002.000; 514/008.000; 514/012.000
NCL NCLM: 514/002.000; 514/008.000; 514/012.000
IC [7] ICM: A61K038-19
EXF 424/85.1; 424/85; 514/2; 514/8; 514/12
FS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 13 OF 24 USPATFULL
AN 2002:362461 USPATFULL
TI 22109, a novel human thioredoxin family member and uses thereof
IN Barak, Rajsekhar, Watertown, MA, United States (U.S. corporation)
PA Millenium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 642187 B1 20021008
AI US 2001-882835 B1 20010615 (9)
PRAI US 2000-211673P 20000615 (60)
DT Utility
FS GRANTED
LN CNT 4616
INCL INCM: 536/023.200
INCL INCM: 536/023.500; 435/233.000
NCL NCLM: 536/023.200

| | | |
|-----|--|--|
| IC | NCLC: 435/233.000; 536/023.500 (7) ICM: C07H021-04 IIC: C12N009-90 EXF: 18232, a novel dual specificity phosphatase and uses therefor CAS INDEXING IS AVAILABLE FOR THIS PATENT. | TI Therapeutic uses of the hypervariable region of monoclonal antibody M195 and constructs thereon: Scheinberg, David A., New York, NY, United States Sloan-Kettering Institute for Cancer Research, New York, NY, United States (U.S. corporation) US 6007814 PI US 1992-861967 AI US 199020615 (7) RJL Continuation-in-part of Ser. No. US 45919 DT Utility FS Granted IN PA |
| L19 | ANSWER 14 OF 24 USPATFULL 2002-174981 USPATFULL 18232, a novel dual specificity phosphatase and uses therefor Meyers, Rachel A., Newton, MA, United States Welch, Nadine, Brookline, MA, United States Millenium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation) US 6620153 AI US 2000-704139 DT US 2000-185772P FS GRANTED LN.CNT 4450 INCL INCLM: 435/196.000 INCLS: 435/232.300; 435/320.100; 435/325.000; 536/023.200; 536/023.100; NCL INCLM: 435/196.000 INCLS: 435/232.300; 435/320.100; 435/325.000; 536/023.100; 536/023.200; IC [7] ICM: C12N009-16 ICGS: C12N001-20; C12N005-00; C07H021-02; C07H021-04 EXP 435/196.20; 435/252.3; 435/320.1; 435/325.000; 536/023.100; 536/023.200; CAS INDEXING IS AVAILABLE FOR THIS PATENT. | IN PA |
| L19 | ANSWER 15 OF 24 USPATFULL 2002-102621 USPATFULL Cell-specific active compounds regulated by the cell cycle TI Sedlacek, Hans-Harald, Marburg, GERMANY, FEDERAL REPUBLIC OF Mueller, Rolf, Marburg, GERMANY, FEDERAL REPUBLIC OF PA Hoenck Aktiengesellschaft, Frankfurt am Main, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation) PI US 6364202 WO 9606941 19960307 AI US 1997-733109 19970425 (8) WO 1995-EP3371 19950225 PRAI GB 1994-17366 19940826 DE 1995-6666 19950329 DE 1995-1952470 19950712 DT UTILITY FS GRANTED LN.CNT 2654 INCL INCLM: 536/023.100; 424/093.200; 424/093.600; 435/320.100; 536/023.500; INCLS: 424/093.100; 424/093.200; 424/093.600; 435/320.100; 536/023.500; NCL INCLM: 536/023.100 INCLS: 424/093.100; 424/093.200; 424/093.600; 435/320.100; 536/023.500; IC [7] ICM: A01N063-00 ICGS: A61K048-00; C07H021-02; C12N015-63 EXP 536/23.5; 536/24.1; 536/23.1; 514/44; 435/320.1; 424/93.1; 424/93.2; CAS INDEXING IS AVAILABLE FOR THIS PATENT. | IN PA |
| L19 | ANSWER 16 OF 24 USPATFULL 1999-170208 USPATFULL IN PA | IN PA |
| IC | [6] ICM: C07K016-00 IIC: A01N043-04; C12P019-44 EXP 530/391.1; 530/391.7; 514/25; 514/26; 514/53; 514/168 ANSWER 18 OF 24 USPATFULL 1998-75158 USPATFULL TI CAS INDEXING IS AVAILABLE FOR THIS PATENT. Hammann, Philip Ross, Garnerville, NY, United States IN PA | IN PA |

Hollander, Irwin, Monsey, NY, United States
 Holcomb, Ryan, Glen Rock, NJ, United States
 Hallett, William, New City, NY, United States
 Tsou, Hwei-Ru, New City, NY, United States
 Weiss, Martin J., Ft. Lee, NJ, United States
 American Cyanamid Company, Madison, NJ, United States (U.S. corporation)
 US 5737001 19980630 1994-253877
 AI Utility
 FS Granted
 LN.CNT 3777
 INCL INCLM: 424/181.100
 INCLS: 514/025.000; 514/053.000; 514/054.000; 514/061.000; 514/069.000;
 NCL NCLM: 530/391.100; 530/402.000; 536/16.800
 NCLM: 424/181.100
 NCLS: 514/025.000; 514/053.000; 514/054.000; 514/061.000; 514/069.000;
 ICM: A61K039-395
 ICS: C07K016-000; C07K011-00
 EXP 530/391.9; 530/399; 530/402.424/181.1; 514/12; 514/25.26; 514/169.53;
 514/54.61; 552/500; 435/74; 536/16.8; 536/17.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 19 OF 24 USPATFULL
 1998-69196 USPATFULL
 Linkers useful for the synthesis of conjugates of methyltrithio
 antitumor agents

IN Hamann, Philip Ross, Garverville, NY, United States
 Hinman, Lois N, Tarrytown, NY, United States
 Hollander, Irwin, Monsey, NY, United States
 Holcomb, Ryan, Glen Rock, NJ, United States
 Hallett, William, New City, NY, United States
 Tsou, Hwei-Ru, New City, NY, United States
 Weiss, Martin J., Ft. Lee, NJ, United States (U.S. corporation)
 American Cyanamid Company, Madison, NJ, United States
 US 5767285 19980616 1995-462939
 AI US 1995-462939 (8)
 RLI Division of Ser. No. US 1994-253877, filed on 3 Jun 1994
 DR Utility
 FS Granted
 LN.CNT 2848
 INCL INCLM: 549/542.000
 INCLS: 544/030.000; 560/019.000; 564/152.000; 564/163.000; 530/391.900;
 NCL NCLM: 530/402.000
 NCLS: 50/391.900; 530/402.000; 544/038.000; 560/019.000; 564/152.000;
 564/163.000
 ICM: A61K039-46
 ICS: C07D207-46; C07D295-22
 EXP 530/391.9; 530/399; 530/402; 514/12; 514/25; 514/26; 514/54; 514/61;
 514/153; 514/169; 544/38; 548/542; 560/19; 564/152; 564/163
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 20 OF 24 USPATFULL
 1998-39508 USPATFULL
 Enedine derivatives useful for the synthesis of conjugates of
 methyltrithio antitumor agents

IN Hamann, Philip Ross, Garverville, NY, United States
 Hinman, Lois, Tarrytown, NY, United States
 Hollander, Irwin, Monsey, NY, United States
 Holcomb, Ryan, Glen Rock, NJ, United States
 Hallett, William, New City, NY, United States
 Tsou, Hwei-Ru, New City, NY, United States

Weiss, Martin J., Ft. Lee, NJ, United States
 American Cyanamid Company, Madison, NJ, United States (U.S. corporation)
 PA US 5739116 19980414 1994-253877, filed on 3 Jun 1994
 PI US 5739116 19980414 1994-253877, filed on 3 Jun 1994
 AI US 1995-461284
 RLI Division of Ser. No. US 1994-253877, filed on 3 Jun 1994
 DT Utility
 FS Granted
 LN.CNT 2862
 INCL INCLM: 514/025.000
 INCLS: 514/005.000; 514/012.000; 514/053.000; 514/056.000; 514/061.000;
 NCL NCLM: 514/025.000
 NCLS: 424/178.100; 536/016.800; 536/017.500
 ICM: A61K039-00
 ICS: A01N043-00; A61K039-00; C12P019-44
 EXP 530/391.7; 530/399; 530/402; 514/12; 514/25; 514/26; 514/54; 514/61;
 514/165.53; 514/5; 514/53; 424/178.1; 536/16.8; 536/17.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 21 OF 24 USPATFULL
 1998-30697 USPATFULL
 Therapeutic use of hypervariable region of monoclonal antibody
 M105 and constructs thereof

IN Scheinberg, David A., New York, NY, United States
 PA Sloan-Kettering Institute for Cancer Research, New York, NY, United
 States (U.S. corporation)
 PI US 5730982
 AI US 1995-303615
 RLI Continuation of Ser. No. US 1993-56957, filed on 3 May 1993, now
 abandoned which is a continuation of Ser. No. US 1989-450918, filed on
 14 Dec 1989, now abandoned
 DT Utility
 FS Granted
 LN.CNT 2528
 INCL INCLM: 424/181.100
 INCLS: 424/183.100; 530/388.220; 530/391.300; 530/391.500; 530/391.700;
 NCL NCLM: 424/181.100
 NCLS: 424/183.100; 530/388.220; 530/391.300; 530/391.500; 530/391.700;
 530/391.900
 ICM: A61K039-395
 ICS: C07K016-28
 EXP 530/391.3; 530/391.7; 530/387.7; 530/387.3; 530/388.22;
 530/391.5; 530/391.9; 435/240.27; 424/178.1; 424/181.1; 424/184.1;
 424/154.1; 424/155.1; 424/181.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 22 OF 24 USPATFULL
 1997-94073 USPATFULL
 Methods of obtaining compositions enriched for hematopoietic stem cells,
 compositions derived therefrom and methods of use thereof

IN Simmons, Paul J., Adelaide, Australia
 Hill, Beth L., Mountain View, CA, United States
 PA Systemix, Inc., Palo Alto, CA, United States (U.S. corporation)
 PI US 5677136 19971014 19971014
 AI US 1994-34047
 DT Utility
 FS Granted
 LN.CNT 1556
 INCL INCLM: 435/007.240
 INCLS: 435/002.000; 435/030.000; 435/240.200; 435/240.270; 530/388.700

NCL NCLM: 435/007-240
 NCLS: 435/002.000; 435/030.000; 435/343.000; 435/372.000; 530/388.700
 IC I61
 ICM: C07K016-28
 ICS: C12N005-08; C12Q001-24
 EXP 435/2; 435/7.24; 435/30; 435/240.2; 435/240.27; 530/388.7
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 23 OF 24 USPATFULL
 97-44908 USPATFULL
 WTI monoclonal antibodies and methods of use therefor
 IN Herlyn, Meenhard, Wynnewood, PA, United States
 Morris, Jennifer, Brookfield, WI, United States
 Rauscher, III, Frank J., Cranbury, NJ, United States
 Rodeck, Ulrich, Philadelphia, PA, United States
 PA The Wistar Institute of Anatomy and Biology, Philadelphia, PA, United States (U.S. corporation)
 PI US 563142 19970527
 AI US 1995-456907 19950601 (8)
 Continuation-in-part of Ser. No. US 1994-234783, filed on 28 Apr 1994
 DT Utility
 FS Granted
 LN CNT 1214
 INCL INCLM: 435/007-230
 INCLS: 435/007-230
 NCL NCLM: 435/007-230
 NCLS: 530/388.100; 530/388.800; 530/809.000
 IC [6] ICM: G01N033-547
 ICS: G01N033-53; C07K016-30; C07K016-18
 EXP 435/7.23; 435/7.1; 435/7.21; 435/7.2; 435/7.1; 530/387.1; 530/388.8; 530/409
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 24 OF 24 USPATFULL
 97-33630 USPATFULL
 WTI monoclonal antibodies
 IN Herlyn, Meenhard, Wynnewood, PA, United States
 Morris, Jennifer, Wilmington, DE, United States
 Rauscher, III, Frank J., Cranbury, NJ, United States
 Rodeck, Ulrich, Philadelphia, PA, United States
 PA The Wistar Institute of Anatomy & Biology, Philadelphia, PA, United States (U.S. corporation)
 PI US 562835 19970422
 AI US 1994-234783 19940428 (8)
 DT Utility
 FS Granted
 LN CNT 1265
 INCL INCLM: 435/328.000
 INCLS: 530/387.300; 530/387.900; 530/388.100; 530/388.800; 530/388.850;
 NCL NCLM: 435/070.210; 435/172.200; 435/331.000; 435/344.000; 435/344.100;
 NCLS: 530/387.330; 530/387.900; 530/388.100; 530/388.800; 530/388.850
 IC [6] ICM: C12N005-12
 ICS: C07K016-00; C07K016-18; C07K016-30
 EXP 435/240.27; 435/172.2; 435/70.21; 435/7.23; 530/387.3; 530/387.9; 530/388.1; 530/388.85; 530/388.8
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 14:13:41 ON 12 FEB 2003)

FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, CAPLUS, EMBASE, USPATFULL'

L1

ENTERED AT 14:14:19 ON 12 FEB 2003

L2 1723 S GRANULOCYTE (A) ANTIBODY

L3 17 S LI AND CML

L4 14 DUP REM L2 (3 DUPLICATES REMOVED)

L5 22 S LI AND MN3

L6 16 DUP REM L4 (6 DUPLICATES REMOVED)

L7 293 S LI AND ADMINISTRAT?

L8 282 DUP REM L6 (11 DUPLICATES REMOVED)

L9 282 S 17 NOT YP=>2000

L10 234 S 17 NOT PI=>2000

L11 2 S 19 AND MN3 (A) 90

L12 10 S L9 AND NCA

L13 32001 S CML

L14 3824 S LI2 AND GRANULOCYTE

L15 831 S LI3 AND ANTIBOD?

L16 23 S LI4 AND NCA?

L17 18 DUP REM L15 (5 DUPLICATES REMOVED)

L18 204 S LI4 AND HUMANIZ?

L19 24 DUP REM L18 (0 DUPLICATES REMOVED)

L20 => S 114 and treat?

L21 => S 120 and MN3

L22 => S 120 and MN2

=> d 1 ab

L22 ANSWER 1 OF 1 USPATFULL

AB The invention provides isolated nucleic acids molecules, designated 56294 and 56229 nucleic acid molecules, which encode novel metalloprotease family members. The invention also provides anti sense nucleic acid molecules, recombinant expression vectors containing 56294 or 56229 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 56294 or 56229 gene has been introduced or disrupted. The invention still further provides isolated 56294 or 56229 proteins, fusion proteins, antigenic peptides and anti-56294, anti-56229 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

=> d 1 ibib

L22 ANSWER 1 OF 1 USPATFULL
 ACCESSION NUMBER: 2003-23732 USPATFULL

TITLE: 56294 and 56229, novel human metalloproteases and uses thereof

INVENTOR(S): Bandaru, Rajsekhar, Watertown, MA, UNITED STATES

| NUMBER | KIND | DATE |
|----------------|------|--------------|
| US 2003017572 | A1 | 20030123 |
| US 2001-951656 | A1 | 20010924 (9) |

IN progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
 Li, Haodong, Gaithersburg, MD, United States
 Ruben, Steven M., Olney, MD, United States (U.S.)
 Human Genome Sciences, Inc., Rockville, MD, United States (U.S.)
 RLI
 PA
 PI US 2000-686693 B1 2001013 (9)
 Continuation of Ser. No. US 2000-57103, filed on 15 May 2000
 Continuation-in-part of Ser. No. US 1999-33451, filed on 17 Jun 1999
 Continuation of Ser. No. US 1997-941020, filed on 30 Sep 1997, now
 abandoned Continuation-in-part of Ser. No. US 1996-72273, filed on 30
 Sep 1996, now abandoned Continuation-in-part of Ser. No. US 1996-722719,
 filed on 30 Sep 1996, now patented. Pat. No. US 6001606
 Continuation-in-part of Ser. No. US 1995-46875, filed on 6 Jun 1995,
 now abandoned Continuation-in-part of Ser. No. US 1995-46582, filed on
 6 Jun 1995, now abandoned Continuation-in-part of Ser. No. US
 1995-46881, filed on 5 May 1995, now abandoned Continuation-in-part of
 Ser. No. US 46875 Continuation-in-part of Ser. No. US 46582
 Continuation-in-part of Ser. No. US 46881 Continuation of Ser. No. US
 44681 Continuation-in-part of Ser. No. US 1994-208339, filed on 8 Mar
 1994, now patented. Pat. No. US 550403 Continuation of Ser. No. US
 44681 Continuation-in-part of Ser. No. US 208339 Continuation-in-part
 of Ser. No. US 208339
 PRAI US 2000-212650P 20000619 (60)
 US 2000-211450P 20000613 (60)
 US 2000-189142P 20000424 (60)
 US 2000-189048P 20000314 (60)
 US 1999-172063P 19991223 (60)
 US 1999-164052P 19991108 (60)
 US 1999-159362P 19991014 (60)
 DT UTILITY
 FS GRANTED
 LN.CNT 14198
 INCL INCHM: 424/085.100
 INCHS: 424/085.000; 514/002.000; 514/008.000; 514/012.000
 NCL NCLM: 424/085.100
 NCLS: 514/002.000; 514/008.000; 514/012.000
 IC [71] ICM: A61K038-1
 EXP 424/85.1; 424/885; 514/2; 514/8; 514/12
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 6 OF 13 USPATFULL
 AN 2002-297455 USPATFULL
 TI Methods and compositions for making dendritic cells from expanded
 populations of monocytes and for activating T cells
 IN Nelson, Edward L., Eldersburg, MD, United States
 PA Strobl, Susan L., Hagerstown, MD, United States
 The United States of America as represented by the Secretary of the
 Department of Health and Human Services, Washington, DC, United States
 (U.S. Government) B1 20021112
 PI US 64-7286 2000-424173 19991126
 AI US 9853048 199910311 20000605 (9)
 WO 1999-US59810311 19990520
 PRAI US 1997-47348P 19970521 (60)
 DT UTILITY
 FS GRANTED
 LN.CNT 2385 INCHM: 435/377.000
 INCHS: 435/335.000; 435/375.000; 435/455.000; 424/093.100; 424/093.400;
 NCL NCLM: 435/377.000
 NCLS: 424/093.100; 424/093.400; 424/093.710; 435/325.000; 435/375.000;

IN progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
 Li, Haodong, Gaithersburg, MD, United States
 Ruben, Steven M., Olney, MD, United States (U.S.)
 Human Genome Sciences, Inc., Rockville, MD, United States (U.S.)
 RLI
 PA
 PI US 2000-686693 B1 2001013 (9)
 Continuation of Ser. No. US 2000-57103, filed on 15 May 2000
 Continuation-in-part of Ser. No. US 1999-33451, filed on 17 Jun 1999
 Continuation of Ser. No. US 1997-941020, filed on 30 Sep 1997, now
 abandoned Continuation-in-part of Ser. No. US 1996-72273, filed on 30
 Sep 1996, now abandoned Continuation-in-part of Ser. No. US 1996-722719,
 filed on 30 Sep 1996, now patented. Pat. No. US 6001606
 Continuation-in-part of Ser. No. US 1995-46875, filed on 6 Jun 1995,
 now abandoned Continuation-in-part of Ser. No. US 1995-46582, filed on
 6 Jun 1995, now abandoned Continuation-in-part of Ser. No. US
 1995-46881, filed on 5 May 1995, now abandoned Continuation-in-part of
 Ser. No. US 46875 Continuation-in-part of Ser. No. US 46582
 Continuation-in-part of Ser. No. US 46881 Continuation of Ser. No. US
 44681 now patented. Pat. No. US 550403 Continuation of Ser. No. US
 44681 Continuation-in-part of Ser. No. US 208339 Continuation-in-part
 of Ser. No. US 208339
 PRAI US 2000-212650P 20000619 (60)
 US 2000-211450P 20000613 (60)
 US 2000-189142P 20000424 (60)
 US 2000-189048P 20000314 (60)
 US 1999-172063P 19991223 (60)
 US 1999-164052P 19991108 (60)
 US 1999-159362P 19991014 (60)
 DT UTILITY
 FS GRANTED
 LN.CNT 3356
 INCL INCHM: 424/093.100
 INCHS: 424/093.210; 514/002.000; 514/044.000; 435/325.000
 NCL NCLM: 424/093.100
 NCLS: 424/093.210; 435/325.000; 514/002.000; 514/044.000
 IC [71] ICM: A61K038-00
 EXP ICS: A61K048-00; C12N015-85
 424/93.21; 424/93.1; 514/2; 514/44
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 8 OF 13 USPATFULL
 AN 2001-170889 USPATFULL
 TI Monocyte-derived dendrite cell subsets
 IN Punnonen, Juhu, Palo Alto, CA, United States
 Chang, Chia-Chun J., Los Gatos, CA, United States
 PI US 2001-06937 Al 20011004
 AI US 2001-760388 Al 20010110 (9)
 PRAI US 2000-175552P 20000111 (60)
 DT UTILITY
 FS APPLICATION
 LN.CNT 3189
 INCL INCHM: 435/366.000
 INCHS: 435/325.000; 435/373.000; 424/093.210
 NCL NCLM: 435/366.000
 NCLS: 435/325.000; 435/373.000; 424/093.210
 IC [71] ICM: A61K048-00
 ICS: A01N063-00; C12N005-00; C12N005-02

L24 ANSWER 9 OF 13 USPATFULL
 AN 2001-119059 USPATFULL
 TI Immunomodulating compositions for treatment of immune system
 disorders
 IN Rang, Romeo G., Bucharest, Romania
 Percheson, Paul B., Ontario, Canada
 PI US 2001-09680 Al 20010726
 AI US 2001-764010 Al 20010117 (9)
 RLI Continuation of Ser. No. US 1995-404932, filed on 16 Mar 1995, ABANDONED
 DT APPLICATION
 FS APPLICATION
 LN.CNT 3900
 INCL INCHM: 424/528.000

NCL
 IC
 L24
 ANSWER 10 OF 13 USPATFULL
 [71] ICM: A61K035-413
 AN 2000:14974 USPATFULL
 TI Allegeneic cell therapy for cancer following allogeneic stem cell
 IN transplantation, Baxter International Inc., Deerfield, IL, United States (U.S.)
 PA Slavin, Shimon, Jerusalem, Israel
 IN Baxter International Inc., Deerfield, IL, United States (U.S.)
 PA Haddis Medical Research Services and Development Ltd., Jerusalem, Israel (non-U.S. corporation)
 PI US 6143292 20001107
 NO 9637208 19961128
 AI US 1996-9307621 19961121 (8)
 WO 1996-US76521 19960524
 RLI Continuation-in-part of Ser. No. US 1995-449764, filed on 25 May 1995, now abandoned.
 DT Utility
 RS Granted
 INL CNT 134/
 INCL INCLM: 424/093.700
 INCL INCUS: 424/093.700; 424/085.500; 424/085.700; 424/085.200; 424/085.400;
 NCL NCLM: 424/144.100; 424/577.000; 424/578.000; 435/325.000; 435/375.000
 NCL INCUS: 424/093.700
 NCLM: 424/144.100; 424/577.000; 424/578.000; 435/325.000; 435/375.000
 IC [71] ICM: A61K035-28
 ICS: C12N005-08
 EXP 424/93.71; 424/93.7; 424/85.5; 424/85.7; 424/85.2; 424/85.4; 424/144.1; 424/577; 424/578; 435/325; 435/372
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L24
 ANSWER 11 OF 13 USPATFULL
 AN 97-44908 USPATFULL
 TI Wt1 monoclonal antibodies and methods of use therefor
 IN Morris, Jennifer, Brookfield, WI, United States
 Morris, Jennifer, Frank J., Cranbury, NJ, United States
 Rauscher, III, Frank J., Cranbury, NJ, United States
 Rodeck, Ulrich, Philadelphia, PA, United States
 PA The Wistar Institute of Anatomy and Biology, Philadelphia, PA, United States (U.S. corporation)
 PI US 5633142 19950527
 AI US 1995-446907 19950601 (8)
 RLI Continuation-in-part of Ser. No. US 1994-234783, filed on 28 Apr 1994
 DT Utility
 RS Granted
 INL CNT 1214
 INCL INCLM: 435/007.230
 INCL INCUS: 435/007.200; 435/007.210; 530/387.100; 530/387.700;
 NCL NCLM: 435/007.230
 NCL INCUS: 435/007.200; 435/007.210; 530/387.100; 530/387.700;
 IC [61] ICS: GO1N033-53; C07K016-30; C07K016-18
 EXP 435/7.23; 435/7.1; 435/7.2; 435/7.21; 530/387.1; 530/387.7; 530/388.1;
 530/388.8; 530/809
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L24
 ANSWER 12 OF 13 USPATFULL
 AN 97-33650 USPATFULL
 TI Wt1 monoclonal antibodies
 IN Herlyn, Meenhard, Wynnewood, PA, United States
 Morris, Jennifer, Wilmington, DE, United States
 Rauscher, III, Frank J., Cranbury, NJ, United States
 PA The Wistar Institute of Anatomy & Biology, Philadelphia, PA, United States (U.S. corporation)
 PI US 5622835 19970422
 AI US 1994-234783 19940428 (8)
 DT Utility
 FS Granted
 INL CNT 1265
 INCL INCLM: 435/320.000
 INCL INCUS: 530/387.300; 530/387.900; 530/388.100; 530/388.800; 530/388.850;
 EXP 435/1240.27; 435/172.2; 435/7.21; 435/7.23; 530/387.3; 530/387.9;
 NCL NCLM: 435/320.000
 NCL INCUS: 530/387.210; 435/331.000; 435/344.000; 435/344.100; 435/975.000;
 IC [61] ICM: C12N005-12
 INCL INCUS: 530/387.300; 530/387.900; 530/388.100; 530/388.800; 530/388.850;
 EXP 530/388.1; 530/388.85; 530/388.8
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L24
 ANSWER 13 OF 13 USPATFULL
 AN 90-57750 USPATFULL
 TI Latex flow, non-bibulous membrane assay protocols
 IN Eisinger, Robert W., San Diego, CA, United States
 Khalil, Mohammad H., San Diego, CA, United States
 Katz, David H., La Jolla, CA, United States
 Sergeant, Robert B., Ramona, CA, United States
 PA Quertel, Sam Diego, CA, United States (U.S. corporation)
 PI US 494522 19900724
 AI US 1988-220642 19880810 (7)
 RLI Continuation-in-part of Ser. No. US 1987-57273, filed on 1 Jun 1987, now abandoned And a continuation-in-part of Ser. No. US 1987-57271, filed on 1 Jun 1987, now abandoned
 DT Utility
 FS Granted
 INL CNT 1768
 INCL INCLM: 435/007.000
 INCL INCUS: 435/805.000; 435/810.000; 436/512.000; 436/514.000; 436/518.000;
 NCL NCLM: 435/805.000; 436/523.000; 436/531.000; 436/535.000; 436/808.000; 436/810.000; 422/055.000; 422/056.000; 422/057.000;
 NCL INCUS: 435/805.000; 436/523.000; 436/531.000; 436/535.000; 436/808.000; 436/810.000; 422/055.000; 422/056.000; 422/057.000;
 NCL NCLM: 422/056.000; 422/101.000
 NCL INCUS: 422/055.000; 422/056.000; 422/057.000; 422/101.000;
 NCL NCLM: 435/007.250
 NCL INCUS: 435/007.210; 435/007.230; 435/007.320; 435/805.000;
 NCL NCLM: 435/805.000; 436/512.000; 436/514.000; 436/518.000; 436/520.000;
 NCL INCUS: 436/523.000; 436/531.000; 436/535.000; 436/807.000; 436/808.000;
 IC [5] ICM: GO1N033-53
 EXP 422/155-61; 422/70; 422/101; 422/102; 424/11; 435/7; 435/5; 435/805;
 435/806; 436/514-520; 436/512; 436/523; 436/531; 436/535; 436/807;
 436/808; 436/810; 210/431
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 =>

--Logging off of STN--

=> Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

FULL ESTIMATED COST

STN INTERNATIONAL LOGOFF AT 14:48:34 ON 12 FEB 2003

| SINCE FILE ENTRY | TOTAL SESSION |
|------------------|---------------|
| 190.99 | 191.20 |

=> d 17 18 ibib ab

L16 ANSWER 17 OF 18 MEDLINE DUPLICATE 1
ACCESSION NUMBER: 91187141 MEDLINE
DOCUMENT NUMBER: 91187141 PubMed ID: 2011210
TITLE: Distribution of carbohydrate structures in individual maturation stages of myeloid leukemic cells.
AUTHOR: Noworolska A; Slesak B; Harlonzinska A; Richter R
CORPORATE SOURCE: Department of Pathological Anatomy, School of Medicine, Wroclaw, Poland.
SOURCE: NEOPLASMA, (1991) 38 (1) 57-62.
PUB. COUNTRY: Czech Republic
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199105
ENTRY DATE: Entered STN: 19910526
Last Updated on STN: 19960719
Entered Medline: 19910503

AB The distribution of peanut agglutinin (PNA) receptors, nonspecific cross-reacting antigen (NCA) molecule and 3-fucosyl-N-acetyllactosamine (FAL) in myeloid leukemic cells isolated by density gradient centrifugation was compared using immunofluorescence test (IF). Patients with acute myelocytic leukemias (AML) type M2 and M5 showed low percentage of NCA+ and PNA+ cells. In chronic and acute phase of chronic myelocytic leukemias (CML) the number of NCA containing cells increased and the amount of PNA-binding cells decreased as more mature granulocytic fractions were isolated on Ficoll--Uropoline density gradient. In patients with myeloblastic crisis of CML (CML-BC) the number of cells expressing FAL structure did not change in relation to maturation stage of myeloid cells. Our results revealed that the expression of various markers could change in a different way during the differentiation of cells from myeloblasts to mature granulocytes.

L16 ANSWER 18 OF 18 MEDLINE DUPLICATE 2
ACCESSION NUMBER: 82141196 MEDLINE
DOCUMENT NUMBER: 82141196 PubMed ID: 6949877
TITLE: Clinical evaluation of NCA in patients with chronic myelocytic leukemia.
AUTHOR: Wahren B; Gahrton G; Ruden U; Hammarstrom S
SOURCE: INTERNATIONAL JOURNAL OF CANCER, (1982 Feb 15) 29 (2) 133-7.
PUB. COUNTRY: Denmark
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198205
ENTRY DATE: Entered STN: 19900317
Last Updated on STN: 19900317
Entered Medline: 19820512

AB NCA, a normal colon and granulocyte antigen, which has been found in large amounts in myelocytes and metamyelocytes and in smaller amounts in neutrophil granulocytes, was studied in 50 CML patients in various stages of the disease. Radioimmunoassay was used to demonstrate NCA in serum. Untreated CML patients had a mean level of 732 micrograms NCA/l, poorly controlled patients 421 micrograms/l and well-controlled patients 160 mu/l. These values differ significantly from the mean of healthy persons, which was 71 micrograms NCA/l. The serum NCA levels were related to the number of maturing myeloid cells in blood, and to the clinical course in the chronic phase of CML. In blast crisis low

values with a mean of 109 micrograms NCA/l was found. Patients with ANLL had a low mean level, 50 micrograms/l. Low levels of NCA could not be attributed to **antibodies to NCA**.

NCA is a normal myeloid differentiation antigen. Despite this, its occurrence in serum in leukemic patients differs from normal. This probably has to do with the abnormal amount as well as the release of NCA by leukemic maturing myeloid cells.

L21 ANSWER 1 OF 1 MEDLINE
AN 92293167 MEDLINE
DN 92293167 PubMed ID: 1603094
TI Microheterogeneity of a purified IgG1 due to asymmetric Fab glycosylation.
AU Grebenau R C; Goldenberg D M; Chang C H; Koch G A; Gold D V; Kunz A;
Hansen H J
CS Immunomedics Inc., Newark, NJ 07103.
NC CA 39841 (NCI)
SO MOLECULAR IMMUNOLOGY, (1992 Jun) 29 (6) 751-8.
Journal code: 7905289. ISSN: 0161-5890.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199207
ED Entered STN: 19920724
Last Updated on STN: 19920724
Entered Medline: 19920713

=> d 121 ab

L21 ANSWER 1 OF 1 MEDLINE
AB A murine monoclonal anti-granulocyte IgG1, IMMU-**MN3**, was seen to exhibit heterogeneity. On reduced SDS-PAGE, the purified antibody appeared as two heavy-chain bands of unequal intensity, and only one light-chain band. Hydrophobic interaction chromatography (HIC) also resolved two populations of the IMMU-**MN3** antibody. Based on Concanavalin A affinity chromatography, enzymatic digestion with Endoglycosidase F and carbohydrate analysis, it was found that the heterogeneity detected by SDS-PAGE and HIC was due to differences in glycosylation. Furthermore, sequential gel analysis (non-reduced/reduced) demonstrated that the upper heavy-chain band was asymmetrically glycosylated.

L11 ANSWER 8 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 89000602 EMBASE
DOCUMENT NUMBER: 1989000602
TITLE: In vivo labelling of granulocytes using ^{123}I -tagged anti-granulocyte antibodies.
AUTHOR: Seybold K.
CORPORATE SOURCE: Department of Nuclear Medicine, Kantonsspital, CH-5001
Aarau, Switzerland
SOURCE: Nuclear Medicine Communications, (1988) 9/10 (745-752).
ISSN: 0143-3636 CODEN: NMCODC
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal
FILE SEGMENT:
008 Neurology and Neurosurgery
015 Chest Diseases, Thoracic Surgery and Tuberculosis
023 Nuclear Medicine
025 Hematology
026 Immunology, Serology and Transplantation
033 Orthopedic Surgery
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
AB On the basis of previous work with various monoclonal antibodies (Mab) raised against carcinoembryonic antigen (CEA), the anti-CEA Mab 47 was identified which selectively reacted with a surface glycoprotein (95 kDa; NCA 95) of normal human granulocytes. This new tracer was quality tested and radioiodinated with ^{123}I (^{123}I Mab 47) for clinical use according to established procedures. Extended in vitro studies revealed a high selectivity for granulocytes without inhibiting their vital functions. In vivo cell binding to the granulocyte pool was completed very rapidly and remained unchanged over 24 h. For clinical use one dose consisting of 120 mcg of Mab was labelled with 4-5 mCi of ^{123}I . Clinical interest was mainly concentrated on cases of osteomyelitis, infected allografts and abdominal and brain abscesses. After injection of ^{123}I Mab 47, infectious lesions were usually seen after 3-5 h or could be excluded after 24 h. Because of high counting rates the image quality was excellent and single photon emission computerized tomography (SPECT) could be performed for an exact topographical localization of the lesions. No adverse reactions have been seen. It is concluded that there are distinct advantages of the new method compared with scanning of ^{111}In -labelled leucocytes. However, despite this and the low dose of antibodies administered, we recommend restriction of immunoscintigraphy of infectious lesions before a clinically relevant immunization can be excluded.